[S02DA03, antipyrine, The risk or severity of hypertension can be increased when Bromocriptine is combined with Antipyrine.]
[A14AA02, stanozolol, Stanozolol may increase the hypoglycemic activities of Bromocriptine.]
[B01AD01, streptokinase, The risk or severity of adverse effects can be increased when Streptokinase is combined with Bromocriptine.]
[M03AB01, succinylcholine, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Bromocriptine.]
[J01EC02, sulfadiazine, The risk or severity of hypoglycemia can be increased when Sulfadiazine is combined with Bromocriptine.]
[J01ED01, sulfadimethoxine, The therapeutic efficacy of Bromocriptine can be increased when used in combination with Sulfadimethoxine.]
[A07AB03, sulfaguanidine, The therapeutic efficacy of Bromocriptine can be increased when used in combination with Sulfaguanidine.]
[J01ED02, sulfalene, The therapeutic efficacy of Bromocriptine can be increased when used in combination with Sulfametopyrazine.]
[J01ED07, sulfamerazine, The therapeutic efficacy of Bromocriptine can be increased when used in combination with Sulfamerazine.]
[J01EB03, sulfamethazine, The therapeutic efficacy of Bromocriptine can be increased when used in combination with Sulfamethazine.]
[S01AB01, sulfamethizole, The therapeutic efficacy of Bromocriptine can be increased when used in combination with Sulfamethizole.]
[J01EC01, sulfamethoxazole, The risk or severity of hypoglycemia can be increased when Sulfamethoxazole is combined with Bromocriptine.]
[J01ED05, sulfamethoxypyridazine, The therapeutic efficacy of Bromocriptine can be increased when used in combination with Sulfamethoxypyridazine.]
[J01EC03, sulfamoxole, The therapeutic efficacy of Bromocriptine can be increased when used in combination with Sulfamoxole.]
[J01EB04, sulfapyridine, The therapeutic efficacy of Bromocriptine can be increased when used in combination with Sulfapyridine.]
[J01EB01, sulfisomidine, The therapeutic efficacy of Bromocriptine can be increased when used in combination with Sulfaisodimidine.]
[S01AB02, sulfisoxazole, The risk or severity of hypoglycemia can be increased when Sulfisoxazole is combined with Bromocriptine.]
[M01AB02, sulindac, The risk or severity of hypertension can be increased when Sulindac is combined with Bromocriptine.]
[N05AL01, sulpiride, The risk or severity of adverse effects can be increased when Bromocriptine is combined with Sulpiride.]
[N03AX03, sulthiame, The risk or severity of adverse effects can be increased when Bromocriptine is combined with Sulthiame.]
[A10BB04, glibornuride, The risk or severity of hypoglycemia can be increased when Bromocriptine is combined with Glibornuride.]
[A10BC01, glymidine, The therapeutic efficacy of Bromocriptine can be increased when used in combination with Glymidine.]
[M01AX04, apazone, The risk or severity of hypertension can be increased when Bromocriptine is combined with Azapropazone.]
[N05CD07, temazepam, The risk or severity of adverse effects can be increased when Temazepam is combined with Bromocriptine.]
[R03CC03, terbutaline, Bromocriptine may increase the hypertensive and vasoconstricting activities of Terbutaline.]
[G03BA03, testosterone, Testosterone may increase the hypoglycemic activities of Bromocriptine.]
[S01HA03, tetracaine, The risk or severity of adverse effects can be increased when Bromocriptine is combined with Tetracaine.]
[N05AE05, lurasidone, Bromocriptine may increase the hypotensive activities of Lurasidone.]
[A04AD10, dronabinol, The serum concentration of Dronabinol can be increased when it is combined with Bromocriptine.]
[N04BC07, apomorphine, The risk or severity of adverse effects can be decreased when Apomorphine is combined with Bromocriptine.]
[L04AX02, thalidomide, Bromocriptine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[R06AD03, thiethylperazine, The risk or severity of adverse effects can be increased when Bromocriptine is combined with Thiethylperazine.]
[N05CA19, thiopental, Thiopental may increase the hypotensive activities of Bromocriptine.]
[N05AB08, thioproperazine, Bromocriptine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Thioproperazine.]
[N05AC02, thioridazine, Thioridazine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Bromocriptine.]
[N05AF04, thiothixene, The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Thiothixene.]
[G04BE06, moxisylyte, The risk or severity of hypertension can be increased when Bromocriptine is combined with Moxisylyte.]
[N05AL03, tiapride, The risk or severity of adverse effects can be increased when Bromocriptine is combined with Tiapride.]
[N02AX01, tilidine, The risk or severity of adverse effects can be increased when Bromocriptine is combined with Tilidine.]
[S01ED01, timolol, The therapeutic efficacy of Bromocriptine can be increased when used in combination with Timolol.]
[A10BB05, tolazamide, The risk or severity of hypoglycemia can be increased when Tolazamide is combined with Bromocriptine.]
[M02AX02, tolazoline, Tolazoline may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Bromocriptine.]
[V04CA01, tolbutamide, The risk or severity of hypoglycemia can be increased when Tolbutamide is combined with Bromocriptine.]
[M02AA21, tolmetin, The risk or severity of hypertension can be increased when Tolmetin is combined with Bromocriptine.]
[M03BX04, tolperisone, The risk or severity of adverse effects can be increased when Bromocriptine is combined with Tolperisone.]
[N02AX02, tramadol, The metabolism of Tramadol can be decreased when combined with Bromocriptine.]
[N06AF04, tranylcypromine, Tranylcypromine may increase the hypertensive activities of Bromocriptine.]
[N06AX05, trazodone, Trazodone may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Bromocriptine.]
[L01XF01, tretinoin, The risk or severity of adverse effects can be increased when Tretinoin is combined with Bromocriptine.]
[S01BA05, triamcinolone, The risk or severity of hyperglycemia can be increased when Triamcinolone is combined with Bromocriptine.]
[C03DB02, triamterene, The risk or severity of adverse effects can be increased when Triamterene is combined with Bromocriptine.]
[N05CD05, triazolam, The risk or severity of adverse effects can be increased when Triazolam is combined with Bromocriptine.]
[C03AA06, trichlormethiazide, The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Trichlormethiazide.]
[A03AB12, mepenzolate, Bromocriptine may increase the central nervous system depressant (CNS depressant) activities of Mepenzolate.]
[N05AB06, trifluoperazine, Trifluoperazine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Bromocriptine.]
[N05AD02, trifluperidol, The risk or severity of adverse effects can be increased when Bromocriptine is combined with Trifluperidol.]
[N05AA05, triflupromazine, Bromocriptine may increase the central nervous system depressant (CNS depressant) activities of Triflupromazine.]
[S01BA09, clobetasone, The risk or severity of hyperglycemia can be increased when Clobetasone is combined with Bromocriptine.]
[S01BA10, alclometasone, The risk or severity of hyperglycemia can be increased when Alclometasone is combined with Bromocriptine.]
[D07AC02, fluclorolone, The risk or severity of hyperglycemia can be increased when Fluclorolone is combined with Bromocriptine.]
[N04AA01, trihexyphenidyl, Bromocriptine may increase the central nervous system depressant (CNS depressant) activities of Trihexyphenidyl.]
[R03BA07, mometasone, The risk or severity of hyperglycemia can be increased when Mometasone is combined with Bromocriptine.]
[A03AA05, trimebutine, Bromocriptine may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[R06AD01, trimeprazine, The risk or severity of adverse effects can be increased when Bromocriptine is combined with Alimemazine.]
[N03AC02, trimethadione, The risk or severity of hypotension can be increased when Bromocriptine is combined with Trimethadione.]
[C02BA01, trimethaphan, Bromocriptine may decrease the antihypertensive activities of Trimethaphan.]
[N06AA06, trimipramine, Trimipramine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Bromocriptine.]
[R06AX07, triprolidine, The risk or severity of adverse effects can be increased when Triprolidine is combined with Bromocriptine.]
[A03BB01, butylscopolamine, Bromocriptine may increase the central nervous system depressant (CNS depressant) activities of Butylscopolamine.]
[J01FA08, troleandomycin, The serum concentration of Bromocriptine can be increased when it is combined with Troleandomycin.]
[N06AX24, vilazodone, Bromocriptine may increase the vasoconstricting activities of Vilazodone.]
[N06AX02, tryptophan, The risk or severity of adverse effects can be increased when Tryptophan is combined with Bromocriptine.]
[C09CA09, azilsartan medoxomil, Bromocriptine may decrease the antihypertensive activities of Azilsartan medoxomil.]
[M03AA02, tubocurarine, The risk or severity of adverse effects can be increased when Tubocurarine is combined with Bromocriptine.]
[R03DX07, roflumilast, The serum concentration of Roflumilast can be increased when it is combined with Bromocriptine.]
[A10BH05, linagliptin, The metabolism of Bromocriptine can be decreased when combined with Linagliptin.]
[J05AP03, boceprevir, The risk or severity of adverse effects can be increased when Boceprevir is combined with Bromocriptine.]
[J05AP02, telaprevir, The serum concentration of Bromocriptine can be increased when it is combined with Telaprevir.]
[N03AX21, ezogabine, The risk or severity of adverse effects can be increased when Bromocriptine is combined with Ezogabine.]
[R03AC18, indacaterol, Bromocriptine may increase the hypertensive and vasoconstricting activities of Indacaterol.]
[C08DA01, verapamil, Verapamil may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Bromocriptine.]
[N06AX09, viloxazine, The metabolism of Bromocriptine can be decreased when combined with Viloxazine.]
[C04AX07, vincamine, Bromocriptine may decrease the antihypertensive activities of Vincamine.]
[B01AA03, warfarin, The serum concentration of Warfarin can be increased when it is combined with Bromocriptine.]
[N01AX15, xenon, The risk or severity of hypertension can be increased when Bromocriptine is combined with Xenon.]
[C03BA10, xipamide, The therapeutic efficacy of Bromocriptine can be increased when used in combination with Xipamide.]
[N05AF05, zuclopenthixol, Bromocriptine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Zuclopenthixol.]
[J05AE02, indinavir, The serum concentration of Bromocriptine can be increased when it is combined with Indinavir.]
[N03AX14, levetiracetam, The risk or severity of adverse effects can be increased when Bromocriptine is combined with Levetiracetam.]
[L01EC01, vemurafenib, The therapeutic efficacy of Bromocriptine can be increased when used in combination with Vemurafenib.]
[L01ED01, crizotinib, The metabolism of Bromocriptine can be decreased when combined with Crizotinib.]
[J01MA13, trovafloxacin, The therapeutic efficacy of Bromocriptine can be increased when used in combination with Trovafloxacin.]
[N05AE04, ziprasidone, The risk or severity of adverse effects can be increased when Bromocriptine is combined with Ziprasidone.]
[G03AC10, drospirenone, The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Drospirenone.]
[N02BA01, aspirin, The risk or severity of hypoglycemia can be increased when Acetylsalicylic acid is combined with Bromocriptine.]
[G04BD07, tolterodine, Bromocriptine may increase the central nervous system depressant (CNS depressant) activities of Tolterodine.]
[C07AB03, atenolol, The therapeutic efficacy of Bromocriptine can be increased when used in combination with Atenolol.]
[J02AC03, voriconazole, The serum concentration of Bromocriptine can be increased when it is combined with Voriconazole.]
[M03AC04, atracurium, The risk or severity of adverse effects can be increased when Bromocriptine is combined with Atracurium.]
[S01FA01, atropine, Bromocriptine may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[H02AB11, prednylidene, The risk or severity of hyperglycemia can be increased when Prednylidene is combined with Bromocriptine.]
[G04BE10, avanafil, Bromocriptine may increase the hypotensive activities of Avanafil.]
[M03BX01, baclofen, The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Baclofen.]
[A08AA11, lorcaserin, The risk or severity of adverse effects can be increased when Lorcaserin is combined with Bromocriptine.]
[G04BD12, mirabegron, Bromocriptine may increase the hypertensive and vasoconstricting activities of Mirabegron.]
[V03AX03, cobicistat, The serum concentration of Bromocriptine can be increased when it is combined with Cobicistat.]
[J05AJ02, elvitegravir, The serum concentration of Bromocriptine can be increased when it is combined with Elvitegravir.]
[L02BB04, enzalutamide, The serum concentration of Bromocriptine can be decreased when it is combined with Enzalutamide.]
[C01CA18, octopamine, Bromocriptine may increase the hypertensive and vasoconstricting activities of Octopamine.]
[H02AA01, aldosterone, The risk or severity of hyperglycemia can be increased when Aldosterone is combined with Bromocriptine.]
[N05CA04, barbital, Barbital may increase the hypotensive activities of Bromocriptine.]
[J05AE04, nelfinavir, The serum concentration of Bromocriptine can be increased when it is combined with Nelfinavir.]
[S01GA07, brimonidine, Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Bromocriptine.]
[N04BD02, rasagiline, Rasagiline may increase the hypertensive activities of Bromocriptine.]
[C08CA13, lercanidipine, The risk or severity of hypotension can be increased when Bromocriptine is combined with Lercanidipine.]
[A03FA09, mosapride, The risk or severity of adverse effects can be increased when Bromocriptine is combined with Mosapride.]
[N06DA02, donepezil, The risk or severity of adverse effects can be increased when Donepezil is combined with Bromocriptine.]
[N03AX22, perampanel, Perampanel may increase the central nervous system depressant (CNS depressant) activities of Bromocriptine.]
[L04AA29, tofacitinib, The metabolism of Tofacitinib can be decreased when combined with Bromocriptine.]
[N02CC03, zolmitriptan, Bromocriptine may increase the vasoconstricting activities of Zolmitriptan.]
[R06AC06, thonzylamine, Bromocriptine may increase the central nervous system depressant (CNS depressant) activities of Thonzylamine.]
[G04BD10, darifenacin, Bromocriptine may increase the central nervous system depressant (CNS depressant) activities of Darifenacin.]
[N01AA01, ethyl ether, The risk or severity of adverse effects can be increased when Bromocriptine is combined with Diethyl ether.]
[H01CB05, pasireotide, The serum concentration of Bromocriptine can be increased when it is combined with Pasireotide.]
[G04BE03, sildenafil, The risk or severity of hypotension and syncope can be increased when Sildenafil is combined with Bromocriptine.]
[C04AX11, bencyclane, The risk or severity of hypotension can be increased when Bromocriptine is combined with Bencyclane.]
[A10BH04, alogliptin, The risk or severity of hypoglycemia can be increased when Bromocriptine is combined with Alogliptin.]
[C03AA01, bendroflumethiazide, The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Bendroflumethiazide.]
[L04AX06, pomalidomide, The risk or severity of adverse effects can be increased when Bromocriptine is combined with Pomalidomide.]
[N02BA10, benorilate, The risk or severity of hypertension can be increased when Bromocriptine is combined with Benorilate.]
[N05AD07, benperidol, The risk or severity of adverse effects can be increased when Bromocriptine is combined with Benperidol.]
[A10BK02, canagliflozin, Canagliflozin may increase the hypoglycemic activities of Bromocriptine.]
[J01MA15, gemifloxacin, The therapeutic efficacy of Bromocriptine can be increased when used in combination with Gemifloxacin.]
[S01AE07, moxifloxacin, The therapeutic efficacy of Bromocriptine can be increased when used in combination with Moxifloxacin.]
[H03AA04, tiratricol, Tiratricol may decrease the hypoglycemic activities of Bromocriptine.]
[A10AE05, insulin detemir, The risk or severity of hypoglycemia can be increased when Bromocriptine is combined with Insulin detemir.]
[R02AD01, benzocaine, The risk or severity of adverse effects can be increased when Benzocaine is combined with Bromocriptine.]
[A10BX05, pramlintide, The risk or severity of hypoglycemia can be increased when Pramlintide is combined with Bromocriptine.]
[M01AH01, celecoxib, The therapeutic efficacy of Bromocriptine can be increased when used in combination with Celecoxib.]
[N02CC02, naratriptan, Bromocriptine may increase the vasoconstricting activities of Naratriptan.]
[L04AA18, everolimus, The serum concentration of Bromocriptine can be increased when it is combined with Everolimus.]
[N04AC01, benztropine, Bromocriptine may increase the central nervous system depressant (CNS depressant) activities of Benzatropine.]
[L01EC02, dabrafenib, The serum concentration of Bromocriptine can be decreased when it is combined with Dabrafenib.]
[R02AX03, benzydamine, The risk or severity of hypertension can be increased when Bromocriptine is combined with Benzydamine.]
[P03AX06, benzyl alcohol, The risk or severity of adverse effects can be increased when Bromocriptine is combined with Benzyl alcohol.]
[N06AX28, levomilnacipran, The risk or severity of adverse effects can be increased when Bromocriptine is combined with Levomilnacipran.]
[C08EA02, bepridil, The risk or severity of hypotension can be increased when Bromocriptine is combined with Bepridil.]
[C02KX05, riociguat, Bromocriptine may decrease the antihypertensive activities of Riociguat.]
[A10BJ03, lixisenatide, The risk or severity of hypoglycemia can be increased when Bromocriptine is combined with Lixisenatide.]
[C02KX04, macitentan, Bromocriptine may decrease the antihypertensive activities of Macitentan.]
[L01EL01, ibrutinib, The metabolism of Ibrutinib can be decreased when combined with Bromocriptine.]
[N06AX26, vortioxetine, Bromocriptine may increase the vasoconstricting activities of Vortioxetine.]
[G03AC08, etonogestrel, The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Etonogestrel.]
[N03AF04, eslicarbazepine, The risk or severity of adverse effects can be increased when Bromocriptine is combined with Eslicarbazepine.]
[J05AP05, simeprevir, The metabolism of Bromocriptine can be decreased when combined with Simeprevir.]
[N03AG04, vigabatrin, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Bromocriptine.]
[A10BK01, dapagliflozin, Dapagliflozin may increase the hypoglycemic activities of Bromocriptine.]
[C01CA27, droxidopa, Bromocriptine may increase the hypertensive and vasoconstricting activities of Droxidopa.]
[C07AB04, acebutolol, The therapeutic efficacy of Bromocriptine can be increased when used in combination with Acebutolol.]
[N05CH03, tasimelteon, The risk or severity of adverse effects can be increased when Bromocriptine is combined with Tasimelteon.]
[A16AA07, metreleptin, The metabolism of Bromocriptine can be increased when combined with Metreleptin.]
[S03BA03, betamethasone, The risk or severity of hyperglycemia can be increased when Betamethasone is combined with Bromocriptine.]
[S01ED02, betaxolol, The therapeutic efficacy of Bromocriptine can be increased when used in combination with Betaxolol.]
[C02CC01, bethanidine, Bromocriptine may increase the hypertensive and vasoconstricting activities of Bethanidine.]
[A10BJ04, albiglutide, The risk or severity of hypoglycemia can be increased when Bromocriptine is combined with Albiglutide.]
[L01ED02, ceritinib, The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Ceritinib.]
[A03BA03, hyoscyamine, Bromocriptine may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.]
[B01AA07, acenocoumarol, The serum concentration of Acenocoumarol can be increased when it is combined with Bromocriptine.]
[N01AX05, alfaxalone, The risk or severity of adverse effects can be increased when Bromocriptine is combined with Alfaxalone.]
[A10BK03, empagliflozin, Empagliflozin may increase the hypoglycemic activities of Bromocriptine.]
[R03AC19, olodaterol, Bromocriptine may increase the hypertensive and vasoconstricting activities of Olodaterol.]
[D11AA01, glycopyrronium, Bromocriptine may increase the central nervous system depressant (CNS depressant) activities of Glycopyrronium.]
[N05CM19, suvorexant, Bromocriptine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.]
[A16AX10, eliglustat, The metabolism of Eliglustat can be decreased when combined with Bromocriptine.]
[N05AA04, acepromazine, Bromocriptine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Acepromazine.]
[A10BJ05, dulaglutide, The risk or severity of hypoglycemia can be increased when Bromocriptine is combined with Dulaglutide.]
[N04AA02, biperiden, Bromocriptine may increase the central nervous system depressant (CNS depressant) activities of Biperiden.]
[B01AA01, dicumarol, The risk or severity of adverse effects can be increased when Bromocriptine is combined with Dicoumarol.]
[N06AX11, mirtazapine, Bromocriptine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.]
[A03AA09, difemerine, Bromocriptine may increase the central nervous system depressant (CNS depressant) activities of Difemerine.]
[B01AA11, tioclomarol, The risk or severity of adverse effects can be increased when Bromocriptine is combined with Tioclomarol.]
[N05AX16, brexpiprazole, Bromocriptine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Brexpiprazole.]
[G02CX02, flibanserin, Bromocriptine may increase the vasoconstricting activities of Flibanserin.]
[N05AX15, cariprazine, Bromocriptine may increase the vasoconstricting activities of Cariprazine.]
[A10BF01, acarbose, The risk or severity of hypoglycemia can be increased when Acarbose is combined with Bromocriptine.]
[M02AA25, aceclofenac, The risk or severity of hypertension can be increased when Bromocriptine is combined with Aceclofenac.]
[M01AB11, acemetacin, The risk or severity of hypertension can be increased when Bromocriptine is combined with Acemetacin.]
[S01EC01, acetazolamide, The risk or severity of adverse effects can be increased when Acetazolamide is combined with Bromocriptine.]
[A10AE06, insulin degludec, The risk or severity of hypoglycemia can be increased when Bromocriptine is combined with Insulin degludec.]
[N05AB07, acetophenazine, The risk or severity of adverse effects can be increased when Bromocriptine is combined with Acetophenazine.]
[J02AC05, isavuconazole, The metabolism of Bromocriptine can be decreased when combined with Isavuconazole.]
[B01AC27, selexipag, Bromocriptine may decrease the antihypertensive activities of Selexipag.]
[A10BB31, acetohexamide, The risk or severity of hypoglycemia can be increased when Acetohexamide is combined with Bromocriptine.]
[G04CA01, alfuzosin, Bromocriptine may increase the hypotensive activities of Alfuzosin.]
[A03FA05, alizapride, The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Alizapride.]
[N05CA05, aprobarbital, The risk or severity of adverse effects can be increased when Bromocriptine is combined with Aprobarbital.]
[M01AE16, alminoprofen, The risk or severity of hypertension can be increased when Bromocriptine is combined with Alminoprofen.]
[N02BA02, aloxiprin, Aloxiprin may increase the hypoglycemic activities of Bromocriptine.]
[N03AX23, brivaracetam, The risk or severity of adverse effects can be increased when Bromocriptine is combined with Brivaracetam.]
[L01XX52, venetoclax, The metabolism of Bromocriptine can be decreased when combined with Venetoclax.]
[N05BA08, bromazepam, The risk or severity of adverse effects can be increased when Bromocriptine is combined with Bromazepam.]
[S01AA13, fusidic acid, The metabolism of Bromocriptine can be decreased when combined with Fusidic acid.]
[J01MB04, pipemidic acid, The therapeutic efficacy of Bromocriptine can be increased when used in combination with Pipemidic acid.]
[A03AX08, alverine, The risk or severity of adverse effects can be increased when Bromocriptine is combined with Alverine.]
[D07AC11, amcinonide, The risk or severity of hyperglycemia can be increased when Amcinonide is combined with Bromocriptine.]
[R06AB01, brompheniramine, The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Bromocriptine.]
[N06AA19, amineptin, Amineptine may increase the vasopressor activities of Bromocriptine.]
[C08CA01, amlodipine, The risk or severity of hypotension can be increased when Bromocriptine is combined with Amlodipine.]
[N06BX11, aniracetam, The risk or severity of adverse effects can be increased when Bromocriptine is combined with Aniracetam.]
[C03CA02, bumetanide, The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Bumetanide.]
[N01BB01, bupivacaine, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Bromocriptine.]
[C07AA19, bupranolol, The therapeutic efficacy of Bromocriptine can be increased when used in combination with Bupranolol.]
[N07BC01, buprenorphine, Bromocriptine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[L02AE01, buserelin, The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Buserelin.]
[N05BE01, buspirone, The risk or severity of adverse effects can be increased when Buspirone is combined with Bromocriptine.]
[L01XX27, arsenic trioxide, The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Arsenic trioxide.]
[N02AF01, butorphanol, The risk or severity of adverse effects can be increased when Butorphanol is combined with Bromocriptine.]
[J01MA09, sparfloxacin, The therapeutic efficacy of Bromocriptine can be increased when used in combination with Sparfloxacin.]
[S01GX07, azelastine, Bromocriptine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.]
[S01AA26, azithromycin, The serum concentration of Bromocriptine can be increased when it is combined with Azithromycin.]
[L01EF02, ribociclib, The serum concentration of Bromocriptine can be increased when it is combined with Ribociclib.]
[A07EC04, balsalazide, Balsalazide may increase the hypoglycemic activities of Bromocriptine.]
[R03CC12, bambuterol, Bromocriptine may increase the hypertensive and vasoconstricting activities of Bambuterol.]
[N02BF02, pregabalin, The therapeutic efficacy of Bromocriptine can be increased when used in combination with Pregabalin.]
[N03AX30, beclamide, The risk or severity of adverse effects can be increased when Bromocriptine is combined with Beclamide.]
[C09AA07, benazepril, The risk or severity of hypoglycemia can be increased when Benazepril is combined with Bromocriptine.]
[A10BX06, benfluorex, The risk or severity of hypoglycemia can be increased when Bromocriptine is combined with Benfluorex.]
[S01HA02, benoxinate, The risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Bromocriptine.]
[J01XX08, linezolid, Linezolid may increase the hypertensive activities of Bromocriptine.]
[J05AE09, tipranavir, The serum concentration of Bromocriptine can be increased when it is combined with Tipranavir.]
[L01EX10, midostaurin, The serum concentration of Bromocriptine can be increased when it is combined with Midostaurin.]
[N04BD03, safinamide, Safinamide may increase the hypertensive activities of Bromocriptine.]
[J01MA23, delafloxacin, The therapeutic efficacy of Bromocriptine can be increased when used in combination with Delafloxacin.]
[L01XH01, vorinostat, The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Vorinostat.]
[C07AB07, bisoprolol, The therapeutic efficacy of Bromocriptine can be increased when used in combination with Bisoprolol.]
[R03AC17, bitolterol, Bromocriptine may increase the hypertensive and vasoconstricting activities of Bitolterol.]
[J05AG03, efavirenz, The serum concentration of Bromocriptine can be increased when it is combined with Efavirenz.]
[C07AA17, bopindolol, The therapeutic efficacy of Bromocriptine can be increased when used in combination with Bopindolol.]
[N04AA11, bornaprine, Bromocriptine may increase the central nervous system depressant (CNS depressant) activities of Bornaprine.]
[C01DX19, nesiritide, The risk or severity of adverse effects can be increased when Bromocriptine is combined with Nesiritide.]
[A03FA04, bromopride, The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Bromopride.]
[N05AD06, bromperidol, The risk or severity of adverse effects can be increased when Bromocriptine is combined with Bromperidol.]
[N05CD09, brotizolam, The risk or severity of adverse effects can be increased when Bromocriptine is combined with Brotizolam.]
[R03BA02, budesonide, The risk or severity of hyperglycemia can be increased when Budesonide is combined with Bromocriptine.]
[C04AX20, buflomedil, The risk or severity of hypertension can be increased when Bromocriptine is combined with Buflomedil.]
[M01AB07, bumadizone, The risk or severity of hypertension can be increased when Bromocriptine is combined with Bumadizone.]
[N05CA03, butobarbital, The risk or severity of adverse effects can be increased when Bromocriptine is combined with Butobarbital.]
[N06AA15, butriptyline, Butriptyline may increase the vasopressor activities of Bromocriptine.]
[A10BJ06, semaglutide, The risk or severity of hypoglycemia can be increased when Bromocriptine is combined with Semaglutide.]
[A10BK04, ertugliflozin, The therapeutic efficacy of Bromocriptine can be increased when used in combination with Ertugliflozin.]
[N05CA08, butylvinal, The risk or severity of adverse effects can be increased when Bromocriptine is combined with Vinylbital.]
[C09AA01, captopril, Bromocriptine may decrease the antihypertensive activities of Captopril.]
[L02BB05, apalutamide, The metabolism of Bromocriptine can be increased when combined with Apalutamide.]
[N03AF01, carbamazepine, The metabolism of Bromocriptine can be increased when combined with Carbamazepine.]
[A03AA03, camylofine, Bromocriptine may increase the central nervous system depressant (CNS depressant) activities of Camylofin.]
[R06AA08, carbinoxamine, The risk or severity of adverse effects can be increased when Carbinoxamine is combined with Bromocriptine.]
[C07AG02, carvedilol, Carvedilol may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Bromocriptine.]
[B02BX09, fostamatinib, The risk or severity of hypotension and syncope can be increased when Fostamatinib is combined with Bromocriptine.]
[N03AX24, cannabidiol, The risk or severity of adverse effects can be increased when Cannabidiol is combined with Bromocriptine.]
[C07AB08, celiprolol, The therapeutic efficacy of Bromocriptine can be increased when used in combination with Celiprolol.]
[L01XX62, ivosidenib, The metabolism of Bromocriptine can be increased when combined with Ivosidenib.]
[N03AX17, stiripentol, The metabolism of Bromocriptine can be decreased when combined with Stiripentol.]
[S01GX12, cetirizine, The risk or severity of adverse effects can be increased when Cetirizine is combined with Bromocriptine.]
[N05CM04, carbromal, The risk or severity of adverse effects can be increased when Bromocriptine is combined with Carbromal.]
[A10BB06, carbutamide, The risk or severity of hypoglycemia can be increased when Bromocriptine is combined with Carbutamide.]
[N01BA04, chloroprocaine, The risk or severity of adverse effects can be increased when Bromocriptine is combined with Chloroprocaine.]
[R06AA06, chlorphenoxamine, Bromocriptine may increase the central nervous system depressant (CNS depressant) activities of Chlorphenoxamine.]
[M01AC05, lornoxicam, The risk or severity of hypertension can be increased when Bromocriptine is combined with Lornoxicam.]
[M03BA02, carisoprodol, The risk or severity of adverse effects can be increased when Carisoprodol is combined with Bromocriptine.]
[R03BB08, revefenacin, Bromocriptine may increase the central nervous system depressant (CNS depressant) activities of Revefenacin.]
[L01EX13, gilteritinib, The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Gilteritinib.]
[A06AX05, prucalopride, The metabolism of Prucalopride can be decreased when combined with Bromocriptine.]
[C01BG07, cifenline, The risk or severity of hypoglycemia can be increased when Cibenzoline is combined with Bromocriptine.]
[C09AA08, cilazapril, Bromocriptine may decrease the antihypertensive activities of Cilazapril.]
[B01AC23, cilostazol, The metabolism of Cilostazol can be decreased when combined with Bromocriptine.]
[A03FA08, cinitapride, Bromocriptine may increase the vasoconstricting activities of Cinitapride.]
[N06AX27, esketamine, The risk or severity of hypertension can be increased when Esketamine is combined with Bromocriptine.]
[L04AA42, siponimod, The risk or severity of hypertension can be increased when Bromocriptine is combined with Siponimod.]
[J01FA09, clarithromycin, The serum concentration of Bromocriptine can be increased when it is combined with Clarithromycin.]
[N06BA14, solriamfetol, The risk or severity of hypertension can be increased when Solriamfetol is combined with Bromocriptine.]
[N06AX29, brexanolone, The risk or severity of adverse effects can be increased when Bromocriptine is combined with Brexanolone.]
[A03FA06, clebopride, The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Clebopride.]
[N05BA09, clobazam, The risk or severity of adverse effects can be increased when Clobazam is combined with Bromocriptine.]
[D07AB21, clocortolone, The risk or severity of hyperglycemia can be increased when Clocortolone is combined with Bromocriptine.]
[H02AB14, cloprednol, The risk or severity of hyperglycemia can be increased when Cloprednol is combined with Bromocriptine.]
[N05BA22, cloxazolam, The risk or severity of adverse effects can be increased when Bromocriptine is combined with Cloxazolam.]
[C01EB09, ubidecarenone, The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with Bromocriptine.]
[C09CA06, candesartan, Bromocriptine may decrease the antihypertensive activities of Candesartan.]
[H02AB17, cortivazol, The risk or severity of hyperglycemia can be increased when Cortivazol is combined with Bromocriptine.]
[N05AA06, cyamemazine, The risk or severity of adverse effects can be increased when Bromocriptine is combined with Cyamemazine.]
[C03BX03, cicletanine, Bromocriptine may decrease the antihypertensive activities of Cicletanine.]
[M03BX08, cyclobenzaprine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Bromocriptine.]
[N07XX11, pitolisant, The serum concentration of Bromocriptine can be decreased when it is combined with Pitolisant.]
[C03AA09, cyclothiazide, The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Cyclothiazide.]
[G04BE04, yohimbine, The risk or severity of adverse effects can be increased when Bromocriptine is combined with Yohimbine.]
[A10AE03, insulin, regular, pork, The risk or severity of hypoglycemia can be increased when Bromocriptine is combined with Insulin pork.]
[H02AB13, deflazacort, The risk or severity of hyperglycemia can be increased when Deflazacort is combined with Bromocriptine.]
[N02CC08, lasmiditan, The risk or severity of adverse effects can be increased when Lasmiditan is combined with Bromocriptine.]
[G03AC09, desogestrel, The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Desogestrel.]
[B06AX03, voxelotor, The serum concentration of Voxelotor can be increased when it is combined with Bromocriptine.]
[N03AX25, cenobamate, The serum concentration of Bromocriptine can be decreased when it is combined with Cenobamate.]
[R06AB06, dexbrompheniramine, The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Bromocriptine.]
[N02AX03, dezocine, The risk or severity of adverse effects can be increased when Bromocriptine is combined with Dezocine.]
[N05CM21, lemborexant, The risk or severity of adverse effects can be increased when Bromocriptine is combined with Lemborexant.]
[L04AA53, teprotumumab, The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Teprotumumab.]
[N05AD10, lumateperone, The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Lumateperone.]
[S01AE06, gatifloxacin, The therapeutic efficacy of Bromocriptine can be increased when used in combination with Gatifloxacin.]
[J05AE05, amprenavir, The serum concentration of Bromocriptine can be increased when it is combined with Amprenavir.]
[N02CC07, frovatriptan, Bromocriptine may increase the vasoconstricting activities of Frovatriptan.]
[G04CB02, dutasteride, The risk or severity of hypertension can be increased when Dutasteride is combined with Bromocriptine.]
[N05CC04, dichloralphenazone, The risk or severity of adverse effects can be increased when Bromocriptine is combined with Dichloralphenazone.]
[G03DB08, dienogest, The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Dienogest.]
[A07DA04, difenoxin, The risk or severity of adverse effects can be increased when Bromocriptine is combined with Difenoxin.]
[D07AC19, difluprednate, The risk or severity of hyperglycemia can be increased when Difluprednate is combined with Bromocriptine.]
[N02AA08, dihydrocodeine, The risk or severity of adverse effects can be increased when Bromocriptine is combined with Dihydrocodeine.]
[N02CC06, eletriptan, Bromocriptine may increase the vasoconstricting activities of Eletriptan.]
[M01AH02, rofecoxib, The risk or severity of hypertension can be increased when Rofecoxib is combined with Bromocriptine.]
[C08CA16, clevidipine, The risk or severity of hypotension can be increased when Bromocriptine is combined with Clevidipine.]
[C01BD07, dronedarone, Bromocriptine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Dronedarone.]
[N03AG02, dipropylacetamide, The risk or severity of adverse effects can be increased when Bromocriptine is combined with Valpromide.]
[J01FA13, dirithromycin, The serum concentration of Bromocriptine can be increased when it is combined with Dirithromycin.]
[N05BA02, chlordiazepoxide, The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Bromocriptine.]
[C02AA06, methoserpidine, Bromocriptine may decrease the antihypertensive activities of Methoserpidine.]
[L01EH03, tucatinib, The metabolism of Tucatinib can be decreased when combined with Bromocriptine.]
[A03AA08, dihexyverine, Bromocriptine may increase the central nervous system depressant (CNS depressant) activities of Dihexyverine.]
[N04BX04, opicapone, The risk or severity of adverse effects can be increased when Bromocriptine is combined with Opicapone.]
[C01CA14, dopexamine, The risk or severity of adverse effects can be decreased when Bromocriptine is combined with Dopexamine.]
[D07XB03, fluprednidene, The risk or severity of hyperglycemia can be increased when Fluprednidene is combined with Bromocriptine.]
[G04BD09, trospium, Bromocriptine may increase the central nervous system depressant (CNS depressant) activities of Trospium.]
[M01AC04, droxicam, The risk or severity of hypertension can be increased when Bromocriptine is combined with Droxicam.]
[L01EX22, selpercatinib, The risk or severity of hypertension can be increased when Bromocriptine is combined with Selpercatinib.]
[S01BA14, loteprednol, The risk or severity of hyperglycemia can be increased when Loteprednol is combined with Bromocriptine.]
[M02AA27, dexketoprofen, The risk or severity of hypertension can be increased when Bromocriptine is combined with Dexketoprofen.]
[N05CM02, chlormethiazole, The risk or severity of adverse effects can be increased when Bromocriptine is combined with Clomethiazole.]
[M03BB02, chlormezanone, The risk or severity of adverse effects can be increased when Chlormezanone is combined with Bromocriptine.]
[R02AD04, dyclonine, The risk or severity of adverse effects can be increased when Dyclonine is combined with Bromocriptine.]
[C08CA17, levamlodipine, The serum concentration of Levamlodipine can be increased when it is combined with Bromocriptine.]
[N05CD14, remimazolam, The risk or severity of adverse effects can be increased when Bromocriptine is combined with Remimazolam.]
[N07XX04, sodium oxybate, Bromocriptine may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.]
[L04AC19, satralizumab, The serum concentration of Bromocriptine can be decreased when it is combined with Satralizumab.]
[N02AX07, oliceridine, The risk or severity of hypotension, sedation, death, somnolence, and respiratory depression can be increased when Bromocriptine is combined with Oliceridine.]
[C03AA04, chlorothiazide, The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Chlorothiazide.]
[R06AB04, chlorpheniramine, The risk or severity of adverse effects can be increased when Chlorpheniramine is combined with Bromocriptine.]
[N05AA01, chlorpromazine, Chlorpromazine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Bromocriptine.]
[A10BB02, chlorpropamide, The risk or severity of hypoglycemia can be increased when Chlorpropamide is combined with Bromocriptine.]
[N05AF03, chlorprothixene, The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Chlorprothixene.]
[C03BA04, chlorthalidone, The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Chlorthalidone.]
[M03BB03, chlorzoxazone, The risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Bromocriptine.]
[N05BX03, etifoxine, The risk or severity of adverse effects can be increased when Bromocriptine is combined with Etifoxine.]
[N02BA07, ethenzamide, The risk or severity of hypertension can be increased when Bromocriptine is combined with Ethenzamide.]
[N02BA03, choline salicylate, Choline salicylate may increase the hypoglycemic activities of Bromocriptine.]
[N06BX18, vinpocetine, The risk or severity of hypotension can be increased when Bromocriptine is combined with Vinpocetine.]
[N05BA18, ethyl loflazepate, The risk or severity of adverse effects can be increased when Bromocriptine is combined with Ethyl loflazepate.]
[M01AB08, etodolac, The risk or severity of hypertension can be increased when Etodolac is combined with Bromocriptine.]
[M02AA06, etofenamate, The risk or severity of hypertension can be increased when Bromocriptine is combined with Etofenamate.]
[B06AC06, berotralstat, The metabolism of Bromocriptine can be decreased when combined with Berotralstat.]
[A16AX20, lonafarnib, The serum concentration of Bromocriptine can be increased when it is combined with Lonafarnib.]
[L01FX21, naxitamab, The risk or severity of hypertension can be increased when Bromocriptine is combined with Naxitamab.]
[P03AX07, abametapir, The serum concentration of Bromocriptine can be increased when it is combined with Abametapir.]
[C01DX22, vericiguat, The risk or severity of adverse effects can be increased when Bromocriptine is combined with Vericiguat.]
[M03BA05, febarbamate, The risk or severity of adverse effects can be increased when Bromocriptine is combined with Febarbamate.]
[N03AX10, felbamate, The risk or severity of adverse effects can be increased when Felbamate is combined with Bromocriptine.]
[M01AE05, fenbufen, The risk or severity of hypertension can be increased when Bromocriptine is combined with Fenbufen.]
[C01CA19, fenoldopam, The risk or severity of adverse effects can be decreased when Fenoldopam is combined with Bromocriptine.]
[N06BA08, fenozolone, The risk or severity of hypertension can be increased when Bromocriptine is combined with Fenozolone.]
[G04CB01, finasteride, The risk or severity of hypertension can be increased when Bromocriptine is combined with Finasteride.]
[J01MB07, flumequine, The therapeutic efficacy of Bromocriptine can be increased when used in combination with Flumequine.]
[R03BA03, flunisolide, The risk or severity of hyperglycemia can be increased when Flunisolide is combined with Bromocriptine.]
[S02BA08, fluocinolone acetonide, The risk or severity of hyperglycemia can be increased when Fluocinolone acetonide is combined with Bromocriptine.]
[R03CC15, formoterol, Bromocriptine may increase the sympathomimetic activities of Formoterol.]
[A10AF01, insulin, regular, human, The risk or severity of hypoglycemia can be increased when Bromocriptine is combined with Insulin human.]
[N01AB05, trichloroethylene, The risk or severity of adverse effects can be increased when Bromocriptine is combined with Trichloroethylene.]
[H04AA02, dasiglucagon, Bromocriptine may decrease the antihypertensive activities of Dasiglucagon.]
[N02BF01, gabapentin, The risk or severity of adverse effects can be increased when Gabapentin is combined with Bromocriptine.]
[N07CA02, cinnarizine, The risk or severity of hypotension can be increased when Bromocriptine is combined with Cinnarizine.]
[J01MB06, cinoxacin, The therapeutic efficacy of Bromocriptine can be increased when used in combination with Cinoxacin.]
[L01XX73, sotorasib, The serum concentration of Bromocriptine can be decreased when it is combined with Sotorasib.]
[S03AA07, ciprofloxacin, The therapeutic efficacy of Bromocriptine can be increased when used in combination with Ciprofloxacin.]
[N06AB04, citalopram, The risk or severity of adverse effects can be increased when Bromocriptine is combined with Citalopram.]
[H01AC07, somapacitan, The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Somapacitan.]
[C03DA05, finerenone, The serum concentration of Finerenone can be increased when it is combined with Bromocriptine.]
[H01AC09, lonapegsomatropin, The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Lonapegsomatropin.]
[R06AA04, clemastine, The risk or severity of adverse effects can be increased when Clemastine is combined with Bromocriptine.]
[M01AG01, mefenamic acid, The risk or severity of hypertension can be increased when Mefenamic acid is combined with Bromocriptine.]
[A10BB12, glimepiride, The risk or severity of hypoglycemia can be increased when Glimepiride is combined with Bromocriptine.]
[A10BB08, gliquidone, The risk or severity of hypoglycemia can be increased when Bromocriptine is combined with Gliquidone.]
[R03CC13, clenbuterol, Bromocriptine may increase the hypertensive and vasoconstricting activities of Clenbuterol.]
[J01FF01, clindamycin, The serum concentration of Bromocriptine can be increased when it is combined with Clindamycin.]
[N06AX25, St. John's wort extract, The metabolism of Bromocriptine can be increased when combined with St. John's Wort.]
[L03AB15, ropeginterferon alfa-2b, The risk or severity of neuropsychiatric effects can be increased when Ropeginterferon alfa-2b is combined with Bromocriptine.]
[D07AD01, clobetasol, The risk or severity of hyperglycemia can be increased when Clobetasol is combined with Bromocriptine.]
[B06AX04, mitapivat, The therapeutic efficacy of Bromocriptine can be increased when used in combination with Mitapivat.]
[N01BB10, levobupivacaine, The risk or severity of adverse effects can be increased when Levobupivacaine is combined with Bromocriptine.]
[N06AA04, clomipramine, Clomipramine may increase the vasopressor activities of Bromocriptine.]
[N03AE01, clonazepam, The risk or severity of adverse effects can be increased when Clonazepam is combined with Bromocriptine.]
[S01EA04, clonidine, The risk or severity of sedation can be increased when Clonidine is combined with Bromocriptine.]
[C01EB24, mavacamten, The serum concentration of Bromocriptine can be decreased when it is combined with Mavacamten.]
[A10BX16, tirzepatide, The risk or severity of hypoglycemia can be increased when Bromocriptine is combined with Tirzepatide.]
[C03BA03, clopamide, The therapeutic efficacy of Bromocriptine can be increased when used in combination with Clopamide.]
[N05AH06, clothiapine, The risk or severity of adverse effects can be increased when Bromocriptine is combined with Clothiapine.]
[N05BA21, clotiazepam, The risk or severity of adverse effects can be increased when Bromocriptine is combined with Clotiazepam.]
[A04AA01, ondansetron, The risk or severity of adverse effects can be increased when Ondansetron is combined with Bromocriptine.]
[A04AA02, granisetron, The risk or severity of adverse effects can be increased when Granisetron is combined with Bromocriptine.]
[N05AH02, clozapine, Clozapine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Bromocriptine.]
[A10BX01, guar gum, The risk or severity of hypoglycemia can be increased when Bromocriptine is combined with Guar gum.]
[A10BK06, sotagliflozin, The risk or severity of hypoglycemia can be increased when Bromocriptine is combined with Sotagliflozin.]
[N05BA13, halazepam, The risk or severity of adverse effects can be increased when Halazepam is combined with Bromocriptine.]
[D07AC12, halometasone, The risk or severity of hyperglycemia can be increased when Halometasone is combined with Bromocriptine.]
[H01AC08, somatrogon, The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Somatrogon.]
[S02DA02, cocaine, Bromocriptine may increase the central nervous system depressant (CNS depressant) activities of Cocaine.]
[C02KB01, metyrosine, Bromocriptine may increase the sedative activities of Metyrosine.]
[M01AX13, proquazone, The risk or severity of hypertension can be increased when Bromocriptine is combined with Proquazone.]
[R05DA04, codeine, The risk or severity of adverse effects can be increased when Codeine is combined with Bromocriptine.]
[M03AC05, hexafluorenium, The risk or severity of adverse effects can be increased when Hexafluronium is combined with Bromocriptine.]
[M04AC01, colchicine, The metabolism of Colchicine can be decreased when combined with Bromocriptine.]
[A03AB10, hexocyclium, Bromocriptine may increase the central nervous system depressant (CNS depressant) activities of Hexocyclium.]
[A03BB06, homatropine methylbromide, Bromocriptine may increase the central nervous system depressant (CNS depressant) activities of Homatropine methylbromide.]
[N01AB07, desflurane, The risk or severity of adverse effects can be increased when Desflurane is combined with Bromocriptine.]
[A04AA03, tropisetron, The risk or severity of adverse effects can be increased when Bromocriptine is combined with Tropisetron.]
[C04AX28, ifenprodil, The risk or severity of adverse effects can be increased when Bromocriptine is combined with Ifenprodil.]
[A10BX03, nateglinide, The risk or severity of hypoglycemia can be increased when Nateglinide is combined with Bromocriptine.]
[N02BA16, imidazole-2-hydroxybenzoate, The risk or severity of hypertension can be increased when Bromocriptine is combined with Imidazole salicylate.]
[H01AC03, mecasermin, The risk or severity of hypoglycemia can be increased when Mecasermin is combined with Bromocriptine.]
[A10AE04, insulin glargine, The risk or severity of hypoglycemia can be increased when Bromocriptine is combined with Insulin glargine.]
[J01FA15, telithromycin, The serum concentration of Bromocriptine can be increased when it is combined with Telithromycin.]
[R03BA08, ciclesonide, The risk or severity of hyperglycemia can be increased when Ciclesonide is combined with Bromocriptine.]
[B01AC10, indobufen, The risk or severity of hypertension can be increased when Bromocriptine is combined with Indobufen.]
[R06AX27, desloratadine, The risk or severity of adverse effects can be increased when Desloratadine is combined with Bromocriptine.]
[M01AH03, valdecoxib, The risk or severity of hypertension can be increased when Valdecoxib is combined with Bromocriptine.]
[H01AX01, pegvisomant, The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Bromocriptine.]
[A03AX10, isometheptene, Bromocriptine may increase the hypertensive and vasoconstricting activities of Isometheptene.]
[N02CC05, almotriptan, Bromocriptine may increase the vasoconstricting activities of Almotriptan.]
[M01AH04, parecoxib, The risk or severity of hypertension can be increased when Bromocriptine is combined with Parecoxib.]
[J02AC02, itraconazole, The serum concentration of Bromocriptine can be increased when it is combined with Itraconazole.]
[N05BA10, ketazolam, The risk or severity of adverse effects can be increased when Bromocriptine is combined with Ketazolam.]
[M01AA06, kebuzone, The risk or severity of hypertension can be increased when Bromocriptine is combined with Kebuzone.]
[J02AC04, posaconazole, The serum concentration of Bromocriptine can be increased when it is combined with Posaconazole.]
[C08CA09, lacidipine, Bromocriptine may increase the hypotensive activities of Lacidipine.]
[N03AX09, lamotrigine, Bromocriptine may increase the central nervous system depressant (CNS depressant) activities of Lamotrigine.]
[S01BA03, cortisone, The risk or severity of hyperglycemia can be increased when Cortisone is combined with Bromocriptine.]
[N07BC04, lofexidine, The therapeutic efficacy of Bromocriptine can be increased when used in combination with Lofexidine.]
[S01AE04, lomefloxacin, The therapeutic efficacy of Bromocriptine can be increased when used in combination with Lomefloxacin.]
[M01AB09, lonazolac, The risk or severity of hypertension can be increased when Bromocriptine is combined with Lonazolac.]
[N05CD06, lormetazepam, The risk or severity of adverse effects can be increased when Bromocriptine is combined with Lormetazepam.]
[M02AA31, loxoprofen, The risk or severity of hypertension can be increased when Bromocriptine is combined with Loxoprofen.]
[C09AA03, lisinopril, Bromocriptine may decrease the antihypertensive activities of Lisinopril.]
[C08CA11, manidipine, The risk or severity of hypotension can be increased when Bromocriptine is combined with Manidipine.]
[A03AA04, mebeverine, Bromocriptine may increase the central nervous system depressant (CNS depressant) activities of Mebeverine.]
[N06AX13, medifoxamine, The risk or severity of adverse effects can be increased when Bromocriptine is combined with Medifoxamine.]
[S01BA08, medrysone, The risk or severity of hyperglycemia can be increased when Medrysone is combined with Bromocriptine.]
[A08AA09, mefenorex, The risk or severity of hypertension can be increased when Bromocriptine is combined with Mefenorex.]
[C07AA14, mepindolol, The therapeutic efficacy of Bromocriptine can be increased when used in combination with Mepindolol.]
[H02AB15, meprednisone, The risk or severity of hyperglycemia can be increased when Meprednisone is combined with Bromocriptine.]
[C01EB10, adenosine, The risk or severity of Tachycardia can be increased when Adenosine is combined with Bromocriptine.]
[N04AA03, methixene, Bromocriptine may increase the central nervous system depressant (CNS depressant) activities of Metixene.]
[C04AX01, cyclandelate, The risk or severity of hypotension can be increased when Bromocriptine is combined with Cyclandelate.]
[R03CB02, methoxyphenamine, The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Methoxyphenamine.]
[R06AE03, cyclizine, The risk or severity of adverse effects can be increased when Cyclizine is combined with Bromocriptine.]
[N05CA10, cyclobarbital, The risk or severity of adverse effects can be increased when Bromocriptine is combined with Cyclobarbital.]
[C03DA04, eplerenone, Bromocriptine may decrease the antihypertensive activities of Eplerenone.]
[N05AD03, metylperon, The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Melperone.]
[C03AA07, cyclopenthiazide, The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Cyclopenthiazide.]
[J01FA03, midecamycin, The serum concentration of Bromocriptine can be increased when it is combined with Midecamycin.]
[A10BF02, miglitol, The risk or severity of hypoglycemia can be increased when Miglitol is combined with Bromocriptine.]
[N06AX07, minaprine, Minaprine may increase the hypertensive activities of Bromocriptine.]
[S01XA18, cyclosporine, The serum concentration of Cyclosporine can be increased when it is combined with Bromocriptine.]
[N06AG02, moclobemide, Moclobemide may increase the hypertensive activities of Bromocriptine.]
[R06AX02, cyproheptadine, Bromocriptine may increase the central nervous system depressant (CNS depressant) activities of Cyproheptadine.]
[C09AA13, moexipril, Bromocriptine may decrease the antihypertensive activities of Moexipril.]
[C10AA07, rosuvastatin, The therapeutic efficacy of Bromocriptine can be increased when used in combination with Rosuvastatin.]
[M02AA02, mofebutazone, The risk or severity of hypertension can be increased when Bromocriptine is combined with Mofebutazone.]
[M01AX22, morniflumate, The risk or severity of hypertension can be increased when Bromocriptine is combined with Morniflumate.]
[C03XA02, conivaptan, The serum concentration of Bromocriptine can be increased when it is combined with Conivaptan.]
[C02AC05, moxonidine, Bromocriptine may increase the hypertensive and vasoconstricting activities of Moxonidine.]
[G04BE09, vardenafil, The metabolism of Vardenafil can be decreased when combined with Bromocriptine.]
[M01AH05, etoricoxib, The risk or severity of hypertension can be increased when Bromocriptine is combined with Etoricoxib.]
[G03XA01, danazol, The serum concentration of Bromocriptine can be increased when it is combined with Danazol.]
[M03CA01, dantrolene, The risk or severity of adverse effects can be increased when Bromocriptine is combined with Dantrolene.]
[N06BX04, deanol, The risk or severity of adverse effects can be increased when Bromocriptine is combined with Deanol.]
[C02CC04, debrisoquin, Bromocriptine may decrease the antihypertensive activities of Debrisoquine.]
[A04AD11, nabilone, Nabilone may increase the central nervous system depressant (CNS depressant) activities of Bromocriptine.]
[M01AX01, nabumetone, The risk or severity of hypertension can be increased when Nabumetone is combined with Bromocriptine.]
[N05BA16, nordazepam, The risk or severity of adverse effects can be increased when Bromocriptine is combined with Nordazepam.]
[C07AB12, nebivolol, The therapeutic efficacy of Bromocriptine can be increased when used in combination with Nebivolol.]
[N06AX06, nefazodone, Nefazodone may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Bromocriptine.]
[N05CM16, niaprazine, The risk or severity of adverse effects can be increased when Bromocriptine is combined with Niaprazine.]
[C01DX16, nicorandil, Nicorandil may increase the hypotensive activities of Bromocriptine.]
[N03AG06, tiagabine, The risk or severity of adverse effects can be increased when Tiagabine is combined with Bromocriptine.]
[C01CA23, theodrenaline, Bromocriptine may decrease the hypertensive activities of Theodrenaline.]
[M03AC11, cisatracurium, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Bromocriptine.]
[C01CA05, norfenefrine, Bromocriptine may increase the hypertensive and vasoconstricting activities of Norfenefrine.]
[R05DA06, normethadone, The risk or severity of adverse effects can be increased when Bromocriptine is combined with Normethadone.]
[N06AB10, escitalopram, The risk or severity of adverse effects can be increased when Bromocriptine is combined with Escitalopram.]
[G04BD08, solifenacin, Bromocriptine may increase the central nervous system depressant (CNS depressant) activities of Solifenacin.]
[A07EC03, olsalazine, Olsalazine may increase the hypoglycemic activities of Bromocriptine.]
[N06AA01, desipramine, Desipramine may increase the vasopressor activities of Bromocriptine.]
[H01BA02, desmopressin, The risk or severity of hypertension can be increased when Desmopressin is combined with Bromocriptine.]
[S01BA11, desonide, The risk or severity of hyperglycemia can be increased when Desonide is combined with Bromocriptine.]
[D07XC02, desoximetasone, The risk or severity of hyperglycemia can be increased when Desoximetasone is combined with Bromocriptine.]
[H02AA03, desoxycorticosterone, The risk or severity of hyperglycemia can be increased when Desoxycortone is combined with Bromocriptine.]
[C09XA02, aliskiren, Bromocriptine may decrease the antihypertensive activities of Aliskiren.]
[M01AE12, oxaprozin, The risk or severity of hypertension can be increased when Oxaprozin is combined with Bromocriptine.]
[N03AF02, oxcarbazepine, The risk or severity of adverse effects can be increased when Oxcarbazepine is combined with Bromocriptine.]
[S03BA01, dexamethasone, The risk or severity of hyperglycemia can be increased when Dexamethasone is combined with Bromocriptine.]
[N06BX07, oxiracetam, The risk or severity of adverse effects can be increased when Bromocriptine is combined with Oxiracetam.]
[N04AA08, dexetimide, Bromocriptine may increase the central nervous system depressant (CNS depressant) activities of Dexetimide.]
[G04BD04, oxybutynin, Bromocriptine may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[A03AA01, oxyphencyclimine, Bromocriptine may increase the central nervous system depressant (CNS depressant) activities of Oxyphencyclimine.]
[N06BA02, dextroamphetamine, The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Amphetamine.]
[R05DA09, dextromethorphan, The risk or severity of adverse effects can be increased when Dextromethorphan is combined with Bromocriptine.]
[N03AC01, paramethadione, The risk or severity of adverse effects can be increased when Paramethadione is combined with Bromocriptine.]
[N02AC01, dextromoramide, The risk or severity of adverse effects can be increased when Bromocriptine is combined with Dextromoramide.]
[N06AB05, paroxetine, The risk or severity of adverse effects can be increased when Bromocriptine is combined with Paroxetine.]
[N07BC06, heroin, The risk or severity of adverse effects can be increased when Bromocriptine is combined with Diamorphine.]
[N05BA01, diazepam, The risk or severity of adverse effects can be increased when Diazepam is combined with Bromocriptine.]
[N03AX07, phenacemide, The risk or severity of adverse effects can be increased when Phenacemide is combined with Bromocriptine.]
[V03AH01, diazoxide, The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Diazoxide.]
[N03AD02, phensuximide, The risk or severity of adverse effects can be increased when Phensuximide is combined with Bromocriptine.]
[N06AA08, dibenzepin, Dibenzepin may increase the vasopressor activities of Bromocriptine.]
[S02DA04, dibucaine, The risk or severity of adverse effects can be increased when Cinchocaine is combined with Bromocriptine.]
[S01EC02, dichlorphenamide, The therapeutic efficacy of Bromocriptine can be increased when used in combination with Diclofenamide.]
[S01BC03, diclofenac, The risk or severity of hypertension can be increased when Diclofenac is combined with Bromocriptine.]
[A03AA07, dicyclomine, Bromocriptine may increase the central nervous system depressant (CNS depressant) activities of Dicyclomine.]
[A07AB02, phthalylsulfathiazole, The therapeutic efficacy of Bromocriptine can be increased when used in combination with Phthalylsulfathiazole.]
[C02DG01, pinacidil, Bromocriptine may decrease the antihypertensive activities of Pinacidil.]
[A03AX04, pinaverium, The risk or severity of hypotension can be increased when Bromocriptine is combined with Pinaverium.]
[A10BG03, pioglitazone, The risk or severity of hypoglycemia can be increased when Pioglitazone is combined with Bromocriptine.]
[N05AD05, pipamperone, The risk or severity of adverse effects can be increased when Bromocriptine is combined with Pipamperone.]
[A03AB14, pipenzolate, Bromocriptine may increase the central nervous system depressant (CNS depressant) activities of Pipenzolate.]
[L01DC04, ixabepilone, The serum concentration of Bromocriptine can be increased when it is combined with Ixabepilone.]
[R03CC07, pirbuterol, Bromocriptine may increase the hypertensive and vasoconstricting activities of Pirbuterol.]
[C03CA03, piretanide, The therapeutic efficacy of Bromocriptine can be increased when used in combination with Piretanide.]
[A08AA03, diethylpropion, The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Diethylpropion.]
[C08CA03, isradipine, The risk or severity of hypotension can be increased when Bromocriptine is combined with Isradipine.]
[D07XC04, diflucortolone, The risk or severity of hyperglycemia can be increased when Difluocortolone is combined with Bromocriptine.]
[A03AB11, poldine, Bromocriptine may increase the central nervous system depressant (CNS depressant) activities of Poldine.]
[N02BA11, diflunisal, Diflunisal may increase the hypoglycemic activities of Bromocriptine.]
[C02DB01, dihydralazine, Bromocriptine may decrease the antihypertensive activities of Dihydralazine.]
[C04AE04, dihydroergocristine, Dihydroergocristine may increase the hypertensive and vasoconstricting activities of Bromocriptine.]
[N02CA01, dihydroergotamine, Dihydroergotamine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Bromocriptine.]
[N02AA03, hydromorphone, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Bromocriptine.]
[J05AE08, atazanavir, The serum concentration of Bromocriptine can be increased when it is combined with Atazanavir.]
[B01AC21, treprostinil, Bromocriptine may decrease the antihypertensive activities of Treprostinil.]
[D04AB07, pramoxine, The risk or severity of adverse effects can be increased when Bromocriptine is combined with Pramocaine.]
[D07AC18, prednicarbate, The risk or severity of hyperglycemia can be increased when Prednicarbate is combined with Bromocriptine.]
[C08DB01, diltiazem, The risk or severity of hypotension can be increased when Bromocriptine is combined with Diltiazem.]
[R06AA11, dimenhydrinate, The risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Bromocriptine.]
[M03BX03, pridinol, The risk or severity of adverse effects can be increased when Bromocriptine is combined with Pridinol.]
[R06AB03, dimethindene, Bromocriptine may increase the central nervous system depressant (CNS depressant) activities of Dimetindene.]
[R03CC08, procaterol, Bromocriptine may increase the hypertensive and vasoconstricting activities of Procaterol.]
[N03AG05, progabide, The risk or severity of adverse effects can be increased when Progabide is combined with Bromocriptine.]
[N02BB04, propyphenazone, The risk or severity of hypertension can be increased when Bromocriptine is combined with Propyphenazone.]
[M01AB14, proglumetacin, The risk or severity of hypertension can be increased when Bromocriptine is combined with Proglumetacin.]
[R06AA02, diphenhydramine, Bromocriptine may increase the central nervous system depressant (CNS depressant) activities of Diphenhydramine.]
[A07DA01, diphenoxylate, The risk or severity of adverse effects can be increased when Diphenoxylate is combined with Bromocriptine.]
[N05CD10, quazepam, The risk or severity of adverse effects can be increased when Bromocriptine is combined with Quazepam.]
[C09AA06, quinapril, Bromocriptine may decrease the antihypertensive activities of Quinapril.]
[B01AC07, dipyridamole, The risk or severity of hypotension and syncope can be increased when Dipyridamole is combined with Bromocriptine.]
[N06BA11, dexmethylphenidate, The risk or severity of adverse effects can be increased when Dexmethylphenidate is combined with Bromocriptine.]
[N06AA23, quinupramine, Quinupramine may increase the vasopressor activities of Bromocriptine.]
[A03FA02, cisapride, The risk or severity of adverse effects can be increased when Cisapride is combined with Bromocriptine.]
[C09AA05, ramipril, Bromocriptine may decrease the antihypertensive activities of Ramipril.]
[S01XA23, sirolimus, The serum concentration of Bromocriptine can be increased when it is combined with Sirolimus.]
[N05AL04, remoxipride, The risk or severity of adverse effects can be increased when Bromocriptine is combined with Remoxipride.]
[R03CC14, reproterol, Bromocriptine may increase the hypertensive and vasoconstricting activities of Reproterol.]
[C01BA03, disopyramide, Bromocriptine may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[S02AA12, rifamycin SV, The metabolism of Bromocriptine can be increased when combined with Rifamycin.]
[J04AB05, rifapentine, The metabolism of Bromocriptine can be increased when combined with Rifapentine.]
[N07XX02, riluzole, The risk or severity of adverse effects can be increased when Riluzole is combined with Bromocriptine.]
[N05AX08, risperidone, Bromocriptine may increase the hypotensive activities of Risperidone.]
[R06AE09, levocetirizine, The risk or severity of adverse effects can be increased when Bromocriptine is combined with Levocetirizine.]
[N01BB09, ropivacaine, The risk or severity of adverse effects can be increased when Ropivacaine is combined with Bromocriptine.]
[J01MB01, rosoxacin, The therapeutic efficacy of Bromocriptine can be increased when used in combination with Rosoxacin.]
[L01EX01, sunitinib, The risk or severity of hypoglycemia can be increased when Sunitinib is combined with Bromocriptine.]
[A04AD12, aprepitant, The metabolism of Bromocriptine can be decreased when combined with Aprepitant.]
[J05AE07, fosamprenavir, The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Fosamprenavir.]
[G04BE08, tadalafil, The risk or severity of hypotension and syncope can be increased when Tadalafil is combined with Bromocriptine.]
[S01BC05, ketorolac, The risk or severity of hypertension can be increased when Ketorolac is combined with Bromocriptine.]
[C02KX02, ambrisentan, Bromocriptine may decrease the antihypertensive activities of Ambrisentan.]
[N02BA06, salsalate, The risk or severity of hypertension can be increased when Bromocriptine is combined with Salsalate.]
[R03AC12, salmeterol, Bromocriptine may increase the hypertensive and vasoconstricting activities of Salmeterol.]
[C01CA07, dobutamine, Bromocriptine may increase the hypertensive and vasoconstricting activities of Dobutamine.]
[A03FA03, domperidone, The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Domperidone.]
[C01CA04, dopamine, The risk or severity of hypertension can be increased when Dopamine is combined with Bromocriptine.]
[N06AA16, dothiepin, Dosulepin may increase the vasopressor activities of Bromocriptine.]
[R07AB01, doxapram, The risk or severity of hypertension can be increased when Doxapram is combined with Bromocriptine.]
[N06AA12, doxepin, Doxepin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Bromocriptine.]
[R06AA09, doxylamine, Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Bromocriptine.]
[N06AB06, sertraline, The risk or severity of adverse effects can be increased when Bromocriptine is combined with Sertraline.]
[N01AB08, sevoflurane, The risk or severity of adverse effects can be increased when Bromocriptine is combined with Sevoflurane.]
[N05AD08, droperidol, Droperidol may increase the central nervous system depressant (CNS depressant) activities of Bromocriptine.]
[A08AA10, sibutramine, The risk or severity of adverse effects can be increased when Bromocriptine is combined with Sibutramine.]
[C09AA11, spirapril, Bromocriptine may decrease the antihypertensive activities of Spirapril.]
[A07AB04, succinylsulfathiazole, The therapeutic efficacy of Bromocriptine can be increased when used in combination with Succinylsulfathiazole.]
[N05AL02, sultopride, The risk or severity of adverse effects can be increased when Bromocriptine is combined with Sultopride.]
[N02CC01, sumatriptan, Bromocriptine may increase the vasoconstricting activities of Sumatriptan.]
[G01AF05, econazole, The serum concentration of Bromocriptine can be increased when it is combined with Econazole.]
[C07AB13, talinolol, The therapeutic efficacy of Bromocriptine can be increased when used in combination with Talinolol.]
[H01AA01, corticotropin, The risk or severity of hyperglycemia can be increased when Corticotropin is combined with Bromocriptine.]
[J01MA05, temafloxacin, The therapeutic efficacy of Bromocriptine can be increased when used in combination with Temafloxacin.]
[M01AC02, tenoxicam, The risk or severity of hypertension can be increased when Tenoxicam is combined with Bromocriptine.]
[G04CA03, terazosin, Terazosin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Bromocriptine.]
[G04BD05, terodiline, The risk or severity of hypotension can be increased when Bromocriptine is combined with Terodiline.]
[C07AA16, tertatolol, The therapeutic efficacy of Bromocriptine can be increased when used in combination with Tertatolol.]
[S01GA02, tetrahydrozoline, Bromocriptine may increase the hypertensive and vasoconstricting activities of Tetryzoline.]
[M03BX07, tetrazepam, The risk or severity of adverse effects can be increased when Bromocriptine is combined with Tetrazepam.]
[M03BX05, thiocolchicoside, The risk or severity of adverse effects can be increased when Bromocriptine is combined with Thiocolchicoside.]
[N05AB05, thiopropazate, The risk or severity of adverse effects can be increased when Bromocriptine is combined with Thiopropazate.]
[G04BD01, emepronium, Bromocriptine may increase the central nervous system depressant (CNS depressant) activities of Emepronium.]
[N06AX14, tianeptine, Tianeptine may increase the vasopressor activities of Bromocriptine.]
[C09AA02, enalapril, Bromocriptine may decrease the antihypertensive activities of Enalapril.]
[N05BA23, tofisopam, The risk or severity of adverse effects can be increased when Bromocriptine is combined with Tofisopam.]
[M01AG02, tolfenamic acid, The risk or severity of hypertension can be increased when Bromocriptine is combined with Tolfenamic acid.]
[N06AG03, toloxatone, Toloxatone may increase the hypertensive activities of Bromocriptine.]
[N06BA09, atomoxetine, The risk or severity of hypertension can be increased when Atomoxetine is combined with Bromocriptine.]
[N03AX11, topiramate, The risk or severity of adverse effects can be increased when Topiramate is combined with Bromocriptine.]
[C03CA04, torsemide, The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Torasemide.]
[R01AA09, tramazoline, The risk or severity of hypertension can be increased when Bromocriptine is combined with Tramazoline.]
[C09AA10, trandolapril, Bromocriptine may decrease the antihypertensive activities of Trandolapril.]
[N05CD11, triazulenone, The risk or severity of adverse effects can be increased when Bromocriptine is combined with Loprazolam.]
[N05CC01, chloral hydrate, The risk or severity of adverse effects can be increased when Bromocriptine is combined with Chloral hydrate.]
[N05CM07, triclofos, The risk or severity of adverse effects can be increased when Bromocriptine is combined with Triclofos.]
[A03AB08, tridihexethyl, Bromocriptine may increase the central nervous system depressant (CNS depressant) activities of Tridihexethyl.]
[H02CA01, trilostane, The risk or severity of hyperglycemia can be increased when Trilostane is combined with Bromocriptine.]
[R06AA10, trimethobenzamide, The risk or severity of adverse effects can be increased when Trimethobenzamide is combined with Bromocriptine.]
[L02AE04, triptorelin, The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Triptorelin.]
[N04AA12, tropatepine, Bromocriptine may increase the central nervous system depressant (CNS depressant) activities of Tropatepine.]
[R03CC11, tulobuterol, Bromocriptine may increase the hypertensive and vasoconstricting activities of Tulobuterol.]
[N01AB04, enflurane, The risk or severity of adverse effects can be increased when Enflurane is combined with Bromocriptine.]
[C02CA06, urapidil, Bromocriptine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Urapidil.]
[J01MA04, enoxacin, The therapeutic efficacy of Bromocriptine can be increased when used in combination with Enoxacin.]
[N05AL06, veralipride, The risk or severity of adverse effects can be increased when Bromocriptine is combined with Veralipride.]
[S01FB02, ephedrine, Bromocriptine may increase the hypertensive and vasoconstricting activities of Ephedrine.]
[S01GX10, epinastine, The risk or severity of adverse effects can be increased when Epinastine is combined with Bromocriptine.]
[N06AX16, venlafaxine, Venlafaxine may increase the tachycardic activities of Bromocriptine.]
[C01CX07, xamoterol, Bromocriptine may increase the hypertensive and vasoconstricting activities of Xamoterol.]
[S01GA03, xylometazoline, Bromocriptine may increase the hypertensive and vasoconstricting activities of Xylometazoline.]
[C08CA12, mepirodipine, The risk or severity of hypotension can be increased when Bromocriptine is combined with Barnidipine.]
[S01EA01, epinephrine, Bromocriptine may increase the hypertensive and vasoconstricting activities of Epinephrine.]
[C09AA15, zofenopril, Bromocriptine may decrease the antihypertensive activities of Zofenopril.]
[N05CF02, zolpidem, Bromocriptine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.]
[M01AB04, zomepirac, The risk or severity of hypertension can be increased when Bromocriptine is combined with Zomepirac.]
[N03AX15, zonisamide, The risk or severity of hypotension can be increased when Bromocriptine is combined with Zonisamide.]
[A10AB06, insulin glulisine, human, The risk or severity of hypoglycemia can be increased when Bromocriptine is combined with Insulin glulisine.]
[N05CF01, zopiclone, The metabolism of Zopiclone can be decreased when combined with Bromocriptine.]
[N05AX11, zotepine, The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Zotepine.]
[C02AC02, guanfacine, Bromocriptine may increase the hypertensive and vasoconstricting activities of Guanfacine.]
[B01AC11, iloprost, The risk or severity of adverse effects can be increased when Iloprost is combined with Bromocriptine.]
[C01BG01, moricizine, The risk or severity of adverse effects can be increased when Bromocriptine is combined with Moricizine.]
[G02AB03, ergonovine, Bromocriptine may increase the hypertensive and vasoconstricting activities of Ergometrine.]
[C04AE01, ergoloid mesylates, USP, The risk or severity of adverse effects can be decreased when Ergoloid mesylate is combined with Bromocriptine.]
[N02CA02, ergotamine, Ergotamine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Bromocriptine.]
[S01AA17, erythromycin, Erythromycin may increase the vasoconstricting activities of Bromocriptine.]
[N05CD04, estazolam, The risk or severity of adverse effects can be increased when Bromocriptine is combined with Estazolam.]
[G03CA03, estradiol, The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Estradiol.]
[R03BA09, fluticasone furoate, The risk or severity of hyperglycemia can be increased when Fluticasone furoate is combined with Bromocriptine.]
[R03BA05, fluticasone, The risk or severity of hyperglycemia can be increased when Fluticasone is combined with Bromocriptine.]
[C01CA15, gepefrine, The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Gepefrine.]
[N05CM08, ethchlorvynol, The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Bromocriptine.]
[D07AC21, halobetasol, The risk or severity of hyperglycemia can be increased when Ulobetasol is combined with Bromocriptine.]
[L02AA03, ethinyl estradiol, The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Ethinylestradiol.]
[V03AF05, amifostine, The risk or severity of adverse effects can be increased when Amifostine is combined with Bromocriptine.]
[N04AA05, profenamine, Bromocriptine may increase the central nervous system depressant (CNS depressant) activities of Profenamine.]
[N03AD01, ethosuximide, The risk or severity of hypotension can be increased when Bromocriptine is combined with Ethosuximide.]
[N03AB01, ethotoin, The risk or severity of adverse effects can be increased when Ethotoin is combined with Bromocriptine.]
[M01AC06, meloxicam, The risk or severity of hypertension can be increased when Meloxicam is combined with Bromocriptine.]
[S01XA06, ethylmorphine, The risk or severity of adverse effects can be increased when Bromocriptine is combined with Ethylmorphine.]
[C01CA01, etilefrine, Bromocriptine may increase the hypertensive and vasoconstricting activities of Etilefrine.]
[N01AX07, etomidate, Bromocriptine may increase the hypertensive and vasoconstricting activities of Etomidate.]
[N05AE03, sertindole, The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Sertindole.]
[L04AD02, tacrolimus, The serum concentration of Tacrolimus can be increased when it is combined with Bromocriptine.]
[J01MA08, fleroxacin, The therapeutic efficacy of Bromocriptine can be increased when used in combination with Fleroxacin.]
[R06AX12, terfenadine, The serum concentration of Bromocriptine can be increased when it is combined with Terfenadine.]
[N06AX12, bupropion, The risk or severity of adverse effects can be increased when Bupropion is combined with Bromocriptine.]
[N06AB08, fluvoxamine, The risk or severity of adverse effects can be increased when Bromocriptine is combined with Fluvoxamine.]
[L02AE02, leuprolide, The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Leuprolide.]
[C08CA02, felodipine, The risk or severity of hypotension can be increased when Bromocriptine is combined with Felodipine.]
[C08EA01, fendiline, The risk or severity of hypotension can be increased when Bromocriptine is combined with Fendiline.]
[N03AX26, fenfluramine, The risk or severity of adverse effects can be increased when Fenfluramine is combined with Bromocriptine.]
[M01AE04, fenoprofen, The risk or severity of hypertension can be increased when Fenoprofen is combined with Bromocriptine.]
[R03CC04, fenoterol, Bromocriptine may increase the hypertensive and vasoconstricting activities of Fenoterol.]
[N02AB03, fentanyl, The metabolism of Fentanyl can be decreased when combined with Bromocriptine.]
[R03CC02, albuterol, Bromocriptine may increase the hypertensive and vasoconstricting activities of Salbutamol.]
[L01BB06, clofarabine, The risk or severity of adverse effects can be increased when Clofarabine is combined with Bromocriptine.]
[G04BD02, flavoxate, Bromocriptine may increase the central nervous system depressant (CNS depressant) activities of Flavoxate.]
[N02BG04, floctafenine, The risk or severity of hypertension can be increased when Bromocriptine is combined with Floctafenine.]
[J02AC01, fluconazole, The risk or severity of hypoglycemia can be increased when Bromocriptine is combined with Fluconazole.]
[H02AA02, fludrocortisone, The risk or severity of hyperglycemia can be increased when Fludrocortisone is combined with Bromocriptine.]
[D07XB01, flumethasone, The risk or severity of hyperglycemia can be increased when Flumethasone is combined with Bromocriptine.]
[N07CA03, flunarizine, The risk or severity of hypotension can be increased when Bromocriptine is combined with Flunarizine.]
[N05CD03, flunitrazepam, The risk or severity of adverse effects can be increased when Bromocriptine is combined with Flunitrazepam.]
[D07AC08, fluocinonide, The risk or severity of hyperglycemia can be increased when Fluocinonide is combined with Bromocriptine.]
[N06AA14, melitracen, Melitracen may increase the vasopressor activities of Bromocriptine.]
[H02AB03, fluocortolone, The risk or severity of hyperglycemia can be increased when Fluocortolone is combined with Bromocriptine.]
[V03AZ01, ethanol, Bromocriptine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.]
[S01CB05, fluorometholone, The risk or severity of hyperglycemia can be increased when Fluorometholone is combined with Bromocriptine.]
[N06AB03, fluoxetine, Bromocriptine may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[G03BA01, fluoxymesterone, Fluoxymesterone may increase the hypoglycemic activities of Bromocriptine.]
[N05AF01, flupenthixol, The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Flupentixol.]
[N05AB02, fluphenazine, The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Fluphenazine.]
[D07AC07, flurandrenolide, The risk or severity of hyperglycemia can be increased when Flurandrenolide is combined with Bromocriptine.]
[N05CD01, flurazepam, The risk or severity of adverse effects can be increased when Flurazepam is combined with Bromocriptine.]
[S01BC04, flurbiprofen, The risk or severity of hypertension can be increased when Flurbiprofen is combined with Bromocriptine.]
[N05AG01, fluspirilene, The risk or severity of adverse effects can be increased when Bromocriptine is combined with Fluspirilene.]
[N06BX17, adrafinil, Bromocriptine may increase the hypertensive and vasoconstricting activities of Adrafinil.]
[M03AA01, alcuronium, The risk or severity of adverse effects can be increased when Bromocriptine is combined with Alcuronium.]
[G01AX06, furazolidone, Furazolidone may increase the hypertensive activities of Bromocriptine.]
[J05AE10, darunavir, The serum concentration of Bromocriptine can be increased when it is combined with Darunavir.]
[C03CA01, furosemide, The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Furosemide.]
[N05CF04, eszopiclone, The risk or severity of CNS depression can be increased when Bromocriptine is combined with Eszopiclone.]
[N05AL05, amisulpride, The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Amisulpride.]
[M03AC02, gallamine, The risk or severity of adverse effects can be increased when Bromocriptine is combined with Gallamine.]
[C08DA02, gallopamil, The risk or severity of hypotension can be increased when Bromocriptine is combined with Gallopamil.]
[N03AA04, barbexaclone, Barbexaclone may increase the hypotensive activities of Bromocriptine.]
[N06AX08, bifemelane, The risk or severity of adverse effects can be increased when Bromocriptine is combined with Bifemelane.]
[N04BC06, cabergoline, The risk or severity of adverse effects can be decreased when Cabergoline is combined with Bromocriptine.]
[A10BJ02, liraglutide, The risk or severity of hypoglycemia can be increased when Liraglutide is combined with Bromocriptine.]
[N03AD03, methsuximide, The risk or severity of hypotension can be increased when Bromocriptine is combined with Methsuximide.]
[N01AH02, alfentanil, The risk or severity of adverse effects can be increased when Alfentanil is combined with Bromocriptine.]
[A10BB01, glyburide, The risk or severity of hypoglycemia can be increased when Glyburide is combined with Bromocriptine.]
[A10BB09, gliclazide, The risk or severity of hypoglycemia can be increased when Gliclazide is combined with Bromocriptine.]
[A10BB07, glipizide, The risk or severity of hypoglycemia can be increased when Glipizide is combined with Bromocriptine.]
[N05CM18, dexmedetomidine, Bromocriptine may increase the hypertensive and vasoconstricting activities of Dexmedetomidine.]
[N05CE01, glutethimide, The risk or severity of adverse effects can be increased when Bromocriptine is combined with Glutethimide.]
[C05AE01, nitroglycerin, The bioavailability of Bromocriptine can be increased when combined with Nitroglycerin.]
[C02CA04, doxazosin, Doxazosin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Bromocriptine.]
[H01AB01, thyrotropin alfa, Thyrotropin alfa may decrease the hypoglycemic activities of Bromocriptine.]
[C07AB09, esmolol, The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Esmolol.]
[B01AA12, fluindione, The risk or severity of adverse effects can be increased when Bromocriptine is combined with Fluindione.]
[C09AA09, fosinopril, Bromocriptine may decrease the antihypertensive activities of Fosinopril.]
[S01EX01, guanethidine, Bromocriptine may decrease the antihypertensive activities of Guanethidine.]
[L02AE03, goserelin, The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Goserelin.]
[D07AD02, halcinonide, The risk or severity of hyperglycemia can be increased when Halcinonide is combined with Bromocriptine.]
[N05AD01, haloperidol, The risk or severity of CNS depression can be increased when Haloperidol is combined with Bromocriptine.]
[N01AB01, halothane, The risk or severity of adverse effects can be increased when Halothane is combined with Bromocriptine.]
[L02AE05, histrelin, The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Histrelin.]
[N05AH04, quetiapine, Bromocriptine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Quetiapine.]
[A10AD05, insulin aspart, human, The risk or severity of hypoglycemia can be increased when Bromocriptine is combined with Insulin aspart.]
[N02CX03, iprazochrome, The risk or severity of adverse effects can be increased when Bromocriptine is combined with Iprazochrome.]
[N05CA21, allobarbital, The risk or severity of adverse effects can be increased when Bromocriptine is combined with Allobarbital.]
[C09CA01, losartan, Bromocriptine may decrease the antihypertensive activities of Losartan.]
[A07EC02, mesalamine, Mesalazine may increase the hypoglycemic activities of Bromocriptine.]
[N05CA16, hexobarbital, Hexobarbital may increase the hypotensive activities of Bromocriptine.]
[R03CC05, hexoprenaline, Bromocriptine may increase the hypertensive and vasoconstricting activities of Hexoprenaline.]
[C08CA10, nilvadipine, The risk or severity of hypotension can be increased when Bromocriptine is combined with Nilvadipine.]
[M02AA26, nimesulide, The risk or severity of hypotension can be increased when Bromocriptine is combined with Nimesulide.]
[C09AA04, perindopril, Bromocriptine may decrease the antihypertensive activities of Perindopril.]
[C02DB02, hydralazine, Bromocriptine may decrease the antihypertensive activities of Hydralazine.]
[C03AA03, hydrochlorothiazide, The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Hydrochlorothiazide.]
[R05DA03, hydrocodone, Bromocriptine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.]
[S02BA01, hydrocortisone, The risk or severity of hyperglycemia can be increased when Hydrocortisone is combined with Bromocriptine.]
[D07AC16, hydrocortisone aceponate, The risk or severity of hyperglycemia can be increased when Hydrocortisone aceponate is combined with Bromocriptine.]
[D07AB11, hydrocortisone probutate, The risk or severity of hyperglycemia can be increased when Hydrocortisone probutate is combined with Bromocriptine.]
[C03AA02, hydroflumethiazide, The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Hydroflumethiazide.]
[G04BD06, propiverine, Bromocriptine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Propiverine.]
[P01BA02, hydroxychloroquine, The therapeutic efficacy of Bromocriptine can be increased when used in combination with Hydroxychloroquine.]
[N05AX07, prothipendyl, The risk or severity of adverse effects can be increased when Bromocriptine is combined with Prothipendyl.]
[N05BB01, hydroxyzine, Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Bromocriptine.]
[C02AC06, rilmenidine, Bromocriptine may increase the hypertensive and vasoconstricting activities of Rilmenidine.]
[S01BA13, rimexolone, The risk or severity of hyperglycemia can be increased when Rimexolone is combined with Bromocriptine.]
[R02AX02, ibuprofen, The risk or severity of hypertension can be increased when Ibuprofen is combined with Bromocriptine.]
[H01AC02, somatrem, Somatrem may decrease the hypoglycemic activities of Bromocriptine.]
[N01AH03, sufentanil, The risk or severity of adverse effects can be increased when Sufentanil is combined with Bromocriptine.]
[N06AA02, imipramine, Imipramine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Bromocriptine.]
[L01CD01, paclitaxel, The risk or severity of adverse effects can be increased when Bromocriptine is combined with Paclitaxel.]
[R01AD07, tixocortol, The risk or severity of hyperglycemia can be increased when Tixocortol is combined with Bromocriptine.]
[M03BX02, tizanidine, The risk or severity of adverse effects can be increased when Tizanidine is combined with Bromocriptine.]
[C03BA11, indapamide, The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Indapamide.]
[S01BC01, indomethacin, The risk or severity of hypoglycemia can be increased when Indomethacin is combined with Bromocriptine.]
[C02CA02, indoramin, Bromocriptine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Indoramin.]
[N06AX17, milnacipran, The risk or severity of adverse effects can be increased when Bromocriptine is combined with Milnacipran.]
[A03AA30, piperidolate, Bromocriptine may increase the central nervous system depressant (CNS depressant) activities of Piperidolate.]
[N01BB08, articaine, The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Articaine.]
[A10BH01, sitagliptin, The risk or severity of hypoglycemia can be increased when Sitagliptin is combined with Bromocriptine.]
[N05BA12, alprazolam, The metabolism of Alprazolam can be decreased when combined with Bromocriptine.]
[N05CH02, ramelteon, The risk or severity of adverse effects can be increased when Ramelteon is combined with Bromocriptine.]
[R06AE01, buclizine, Bromocriptine may increase the central nervous system depressant (CNS depressant) activities of Buclizine.]
[A10BH02, vildagliptin, The risk or severity of hypoglycemia can be increased when Bromocriptine is combined with Vildagliptin.]
[L01XX35, anagrelide, The risk or severity of Tachycardia can be increased when Anagrelide is combined with Bromocriptine.]
[C07AA01, alprenolol, The therapeutic efficacy of Bromocriptine can be increased when used in combination with Alprenolol.]
[C03BA02, quinethazone, The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Quinethazone.]
[N06AA13, iprindole, Iprindole may increase the vasopressor activities of Bromocriptine.]
[N06AF05, iproniazid, Iproniazid may increase the hypertensive activities of Bromocriptine.]
[N05AA07, chlorproethazine, The risk or severity of adverse effects can be increased when Bromocriptine is combined with Chlorproethazine.]
[N06AF01, isocarboxazid, Isocarboxazid may increase the hypertensive activities of Bromocriptine.]
[R03CC06, isoetharine, Bromocriptine may increase the hypertensive and vasoconstricting activities of Isoetharine.]
[C09AA16, imidapril, Bromocriptine may decrease the antihypertensive activities of Imidapril.]
[N01AB06, isoflurane, The risk or severity of adverse effects can be increased when Isoflurane is combined with Bromocriptine.]
[N04BX02, entacapone, The risk or severity of adverse effects can be increased when Entacapone is combined with Bromocriptine.]
[J04AC01, isoniazid, The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Isoniazid.]
[R03CB01, isoproterenol, Bromocriptine may increase the hypertensive and vasoconstricting activities of Isoprenaline.]
[A10BJ01, exenatide, The risk or severity of hypoglycemia can be increased when Exenatide is combined with Bromocriptine.]
[C01DA14, isosorbide mononitrate, The risk or severity of adverse effects can be increased when Isosorbide mononitrate is combined with Bromocriptine.]
[C05AE02, isosorbide dinitrate, The risk or severity of adverse effects can be increased when Isosorbide dinitrate is combined with Bromocriptine.]
[C04AA01, isoxsuprine, Bromocriptine may increase the hypertensive and vasoconstricting activities of Isoxsuprine.]
[J01FA07, josamycin, The serum concentration of Bromocriptine can be increased when it is combined with Josamycin.]
[N06AX18, reboxetine, The risk or severity of adverse effects can be increased when Reboxetine is combined with Bromocriptine.]
[H01AC01, somatropin, Somatotropin may decrease the hypoglycemic activities of Bromocriptine.]
[N01AX03, ketamine, The risk or severity of adverse effects can be increased when Bromocriptine is combined with Ketamine.]
[C02KD01, ketanserin, The risk or severity of adverse effects can be increased when Bromocriptine is combined with Ketanserin.]
[J02AB02, ketoconazole, The serum concentration of Bromocriptine can be increased when it is combined with Ketoconazole.]
[H02CA04, levoketoconazole, The serum concentration of Bromocriptine can be increased when it is combined with Levoketoconazole.]
[N05AH03, olanzapine, Olanzapine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Bromocriptine.]
[M02AA10, ketoprofen, The risk or severity of hypertension can be increased when Ketoprofen is combined with Bromocriptine.]
[C01CA22, arbutamine, Bromocriptine may increase the hypertensive and vasoconstricting activities of Arbutamine.]
[N04BC09, rotigotine, Bromocriptine may increase the sedative activities of Rotigotine.]
[A16AX01, thioctic acid, The risk or severity of hypoglycemia can be increased when Lipoic acid is combined with Bromocriptine.]
[J01MB02, nalidixic acid, The therapeutic efficacy of Bromocriptine can be increased when used in combination with Nalidixic acid.]
[M01AE11, tiaprofenic acid, The risk or severity of hypertension can be increased when Bromocriptine is combined with Tiaprofenic acid.]
[C07AG01, labetalol, Labetalol may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Bromocriptine.]
[C02AA05, deserpidine, Bromocriptine may decrease the antihypertensive activities of Deserpidine.]
[N03AX18, lacosamide, The risk or severity of adverse effects can be increased when Bromocriptine is combined with Lacosamide.]
[C03CC01, ethacrynic acid, The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Etacrynic acid.]
[G03AD01, levonorgestrel, The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Levonorgestrel.]
[N04BA01, levodopa, The risk or severity of hypotension and orthostatic hypotension can be increased when Bromocriptine is combined with Levodopa.]
[S02DA01, lidocaine, The risk or severity of hypertension can be increased when Bromocriptine is combined with Lidocaine.]
[C08EX01, lidoflazine, The risk or severity of hypotension can be increased when Bromocriptine is combined with Lidoflazine.]
[D06AX13, retapamulin, The metabolism of Retapamulin can be decreased when combined with Bromocriptine.]
[C03DB01, amiloride, The risk or severity of adverse effects can be increased when Amiloride is combined with Bromocriptine.]
[N02CA07, lisuride, The risk or severity of adverse effects can be decreased when Lisuride is combined with Bromocriptine.]
[N06AA07, lofepramine, Lofepramine may increase the vasopressor activities of Bromocriptine.]
[A07DA03, loperamide, The risk or severity of hypotension can be increased when Bromocriptine is combined with Loperamide.]
[N05BA06, lorazepam, The risk or severity of adverse effects can be increased when Lorazepam is combined with Bromocriptine.]
[C10AA02, lovastatin, The metabolism of Lovastatin can be decreased when combined with Bromocriptine.]
[N05AH01, loxapine, The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Loxapine.]
[L01EG01, temsirolimus, The serum concentration of Bromocriptine can be increased when it is combined with Temsirolimus.]
[V04CC02, magnesium sulfate, The therapeutic efficacy of Bromocriptine can be increased when used in combination with Magnesium sulfate.]
[L01EA03, nilotinib, The serum concentration of Bromocriptine can be increased when it is combined with Nilotinib.]
[V04CX04, mannitol, The risk or severity of adverse effects can be increased when Mannitol is combined with Bromocriptine.]
[N06AA21, maprotiline, Bromocriptine may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.]
[A08AA05, mazindol, The risk or severity of adverse effects can be increased when Mazindol is combined with Bromocriptine.]
[C02BB01, mecamylamine, Bromocriptine may decrease the antihypertensive activities of Mecamylamine.]
[R06AE05, meclizine, The risk or severity of adverse effects can be increased when Meclizine is combined with Bromocriptine.]
[M02AA18, meclofenamic acid, The risk or severity of hypertension can be increased when Meclofenamic acid is combined with Bromocriptine.]
[N05BA03, medazepam, The risk or severity of adverse effects can be increased when Bromocriptine is combined with Medazepam.]
[C03BA05, mefruside, The therapeutic efficacy of Bromocriptine can be increased when used in combination with Mefruside.]
[N05CH01, melatonin, The risk or severity of adverse effects can be increased when Melatonin is combined with Bromocriptine.]
[N02AB02, meperidine, The risk or severity of adverse effects can be increased when Meperidine is combined with Bromocriptine.]
[C01CA11, mephentermine, The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Mephentermine.]
[N03AB04, mephenytoin, The risk or severity of adverse effects can be increased when Mephenytoin is combined with Bromocriptine.]
[N03AA01, mephobarbital, Methylphenobarbital may increase the hypotensive activities of Bromocriptine.]
[N01BB03, mepivacaine, The risk or severity of adverse effects can be increased when Mepivacaine is combined with Bromocriptine.]
[N05BC01, meprobamate, The risk or severity of adverse effects can be increased when Meprobamate is combined with Bromocriptine.]
[N02AX05, meptazinol, The risk or severity of adverse effects can be increased when Bromocriptine is combined with Meptazinol.]
[N05AC03, mesoridazine, The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Mesoridazine.]
[G03BB01, mesterolone, Mesterolone may increase the hypoglycemic activities of Bromocriptine.]
[N05AX13, paliperidone, Bromocriptine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Paliperidone.]
[C01CA09, metaraminol, Bromocriptine may increase the hypertensive and vasoconstricting activities of Metaraminol.]
[A10BA02, metformin, The risk or severity of hypoglycemia can be increased when Metformin is combined with Bromocriptine.]
[A04AA04, dolasetron, The risk or severity of adverse effects can be increased when Dolasetron is combined with Bromocriptine.]
[H01CB03, lanreotide, The serum concentration of Bromocriptine can be increased when it is combined with Lanreotide.]
[N07BC02, methadone, The risk or severity of adverse effects can be increased when Methadone is combined with Bromocriptine.]
[N06BA03, methamphetamine, The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Metamfetamine.]
[A03AB07, methantheline, Bromocriptine may increase the central nervous system depressant (CNS depressant) activities of Methantheline.]
[R06AC05, methapyrilene, The risk or severity of adverse effects can be increased when Bromocriptine is combined with Methapyrilene.]
[N05CM01, methaqualone, The risk or severity of adverse effects can be increased when Bromocriptine is combined with Methaqualone.]
[N03AA30, metharbital, The risk or severity of adverse effects can be increased when Metharbital is combined with Bromocriptine.]
[S01EC05, methazolamide, The therapeutic efficacy of Bromocriptine can be increased when used in combination with Methazolamide.]
[G02CB05, metergoline, The risk or severity of adverse effects can be decreased when Bromocriptine is combined with Metergoline.]
[H03BB02, methimazole, The serum concentration of Bromocriptine can be increased when it is combined with Methimazole.]
[M03BA03, methocarbamol, The risk or severity of adverse effects can be increased when Methocarbamol is combined with Bromocriptine.]
[N05CA15, methohexital, Methohexital may increase the hypotensive activities of Bromocriptine.]
[N02BG08, ziconotide, The risk or severity of hypotension can be increased when Bromocriptine is combined with Ziconotide.]
[N05AA02, methotrimeprazine, Bromocriptine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[C01CA10, methoxamine, Bromocriptine may increase the hypertensive and vasoconstricting activities of Methoxamine.]
[N02BG09, methoxyflurane, The risk or severity of adverse effects can be increased when Methoxyflurane is combined with Bromocriptine.]
[C03AA08, methyclothiazide, The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Methyclothiazide.]
[C02AB01, methyldopa, Bromocriptine may increase the hypertensive and vasoconstricting activities of Methyldopa.]
[V04CG05, methylene blue, Methylene blue may increase the hypertensive activities of Bromocriptine.]
[G02AB01, methylergonovine, Methylergometrine may increase the hypertensive and vasoconstricting activities of Bromocriptine.]
[N06BA04, methylphenidate, The risk or severity of adverse effects can be increased when Methylphenidate is combined with Bromocriptine.]
[H02AB04, methylprednisolone, The risk or severity of hyperglycemia can be increased when Methylprednisolone is combined with Bromocriptine.]
[D07AC14, methylprednisolone aceponate, The risk or severity of hyperglycemia can be increased when Methylprednisolone aceponate is combined with Bromocriptine.]
[N03AF03, rufinamide, The risk or severity of adverse effects can be increased when Rufinamide is combined with Bromocriptine.]
[G03EK01, methyltestosterone, Methyltestosterone may increase the hypoglycemic activities of Bromocriptine.]
[N05CE02, methyprylon, The risk or severity of adverse effects can be increased when Methyprylon is combined with Bromocriptine.]
[N02CA04, methysergide, Methysergide may increase the hypertensive and vasoconstricting activities of Bromocriptine.]
[A03FA01, metoclopramide, The risk or severity of sedation can be increased when Metoclopramide is combined with Bromocriptine.]
[C03BA08, metolazone, The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Metolazone.]
[C07AB02, metoprolol, The therapeutic efficacy of Bromocriptine can be increased when used in combination with Metoprolol.]
[N06AX03, mianserin, The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Mianserin.]
[S02AA13, miconazole, The metabolism of Bromocriptine can be decreased when combined with Miconazole.]
[N02BB03, aminopyrine, The risk or severity of hypertension can be increased when Bromocriptine is combined with Aminophenazone.]
[N05CD08, midazolam, The serum concentration of Midazolam can be increased when it is combined with Bromocriptine.]
[C01CA17, midodrine, Bromocriptine may increase the hypertensive and vasoconstricting activities of Midodrine.]
[G03XB01, mifepristone, The serum concentration of Bromocriptine can be increased when it is combined with Mifepristone.]
[C09CA03, valsartan, Bromocriptine may decrease the antihypertensive activities of Valsartan.]
[J01AA08, minocycline, Minocycline may increase the central nervous system depressant (CNS depressant) activities of Bromocriptine.]
[D11AX01, minoxidil, Bromocriptine may decrease the antihypertensive activities of Minoxidil.]
[J01FA11, miocamycin, The serum concentration of Bromocriptine can be increased when it is combined with Miocamycin.]
[L01XX23, mitotane, The metabolism of Bromocriptine can be increased when combined with Mitotane.]
[N06BA12, lisdexamfetamine, The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Lisdexamfetamine.]
[N05AE02, molindone, The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Molindone.]
[L03AC01, aldesleukin, The risk or severity of adverse effects can be increased when Aldesleukin is combined with Bromocriptine.]
[C01BD01, amiodarone, The serum concentration of Bromocriptine can be increased when it is combined with Amiodarone.]
[N06AA09, amitriptyline, Amitriptyline may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Bromocriptine.]
[N02AA01, morphine, The risk or severity of adverse effects can be increased when Morphine is combined with Bromocriptine.]
[A04AA05, palonosetron, The risk or severity of adverse effects can be increased when Palonosetron is combined with Bromocriptine.]
[M03AC03, vecuronium, The risk or severity of adverse effects can be increased when Bromocriptine is combined with Vecuronium.]
[N05CA02, amobarbital, Amobarbital may increase the hypotensive activities of Bromocriptine.]
[G04CA04, silodosin, Bromocriptine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Silodosin.]
[R03BB01, ipratropium bromide, Bromocriptine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N06AA17, amoxapine, Amoxapine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Bromocriptine.]
[N03AB05, fosphenytoin, The metabolism of Bromocriptine can be increased when combined with Fosphenytoin.]
[C07AA12, nadolol, The therapeutic efficacy of Bromocriptine can be increased when used in combination with Nadolol.]
[N04BC04, ropinirole, Bromocriptine may increase the sedative activities of Ropinirole.]
[C04AX21, nafronyl, The risk or severity of adverse effects can be increased when Bromocriptine is combined with Naftidrofuryl.]
[N02AF02, nalbuphine, The risk or severity of adverse effects can be increased when Nalbuphine is combined with Bromocriptine.]
[V03AB15, naloxone, The serum concentration of Bromocriptine can be increased when it is combined with Naloxone.]
[S01XA11, nandrolone, Nandrolone phenpropionate may increase the hypoglycemic activities of Bromocriptine.]
[S01GA01, naphazoline, Bromocriptine may increase the hypertensive and vasoconstricting activities of Naphazoline.]
[N06BA01, amphetamine, The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Amphetamine.]
[M02AA12, naproxen, The risk or severity of hypertension can be increased when Naproxen is combined with Bromocriptine.]
[A10BG01, troglitazone, The risk or severity of hypoglycemia can be increased when Troglitazone is combined with Bromocriptine.]
[N06AX21, duloxetine, The risk or severity of orthostatic hypotension and syncope can be increased when Bromocriptine is combined with Duloxetine.]
[N04BX01, tolcapone, The risk or severity of adverse effects can be increased when Tolcapone is combined with Bromocriptine.]
[N01AH06, remifentanil, The risk or severity of adverse effects can be increased when Remifentanil is combined with Bromocriptine.]
[A10BX02, repaglinide, The risk or severity of hypoglycemia can be increased when Repaglinide is combined with Bromocriptine.]
[C01CX08, levosimendan, The risk or severity of adverse effects can be increased when Levosimendan is combined with Bromocriptine.]
[N05AX14, iloperidone, The metabolism of Iloperidone can be decreased when combined with Bromocriptine.]
[J02AA01, amphotericin B, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Bromocriptine.]
[N06AX23, desvenlafaxine, The risk or severity of adverse effects can be increased when Bromocriptine is combined with Desvenlafaxine.]
[C09CA07, telmisartan, Bromocriptine may decrease the antihypertensive activities of Telmisartan.]
[C10AD02, niacin, The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Niacin.]
[N06AF02, nialamide, Nialamide may increase the hypertensive activities of Bromocriptine.]
[C08CA04, nicardipine, Nicardipine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Bromocriptine.]
[C04AE02, nicergoline, Nicergoline may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Bromocriptine.]
[N07BA01, nicotine, The risk or severity of Tachycardia can be increased when Nicotine is combined with Bromocriptine.]
[C08CA05, nifedipine, The risk or severity of hypotension can be increased when Bromocriptine is combined with Nifedipine.]
[M02AA17, niflumic acid, The risk or severity of hypertension can be increased when Bromocriptine is combined with Niflumic acid.]
[V03AB22, amyl nitrite, The risk or severity of adverse effects can be increased when Bromocriptine is combined with Amyl Nitrite.]
[C08CA06, nimodipine, The risk or severity of hypotension can be increased when Bromocriptine is combined with Nimodipine.]
[C08CA07, nisoldipine, The risk or severity of hypotension can be increased when Bromocriptine is combined with Nisoldipine.]
[N05CD02, nitrazepam, The risk or severity of adverse effects can be increased when Bromocriptine is combined with Nitrazepam.]
[C08CA08, nitrendipine, The risk or severity of hypotension can be increased when Bromocriptine is combined with Nitrendipine.]
[R07AX01, nitric oxide, The risk or severity of adverse effects can be increased when Nitric Oxide is combined with Bromocriptine.]
[N05CF03, zaleplon, The risk or severity of adverse effects can be increased when Zaleplon is combined with Bromocriptine.]
[N04BC05, pramipexole, Bromocriptine may increase the sedative activities of Pramipexole.]
[C02DD01, nitroprusside, Bromocriptine may decrease the antihypertensive activities of Nitroprusside.]
[N01AX13, nitrous oxide, The risk or severity of adverse effects can be increased when Bromocriptine is combined with Nitrous oxide.]
[N06AX04, nomifensine, The risk or severity of adverse effects can be increased when Bromocriptine is combined with Nomifensine.]
[C01CA03, norepinephrine, Bromocriptine may increase the hypertensive and vasoconstricting activities of Norepinephrine.]
[G03DC02, norethindrone, The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Norethisterone.]
[S01AE02, norfloxacin, The therapeutic efficacy of Bromocriptine can be increased when used in combination with Norfloxacin.]
[C02KX01, bosentan, The therapeutic efficacy of Bromocriptine can be increased when used in combination with Bosentan.]
[N06AA10, nortriptyline, Nortriptyline may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Bromocriptine.]
[G02CA02, nylidrin, Bromocriptine may increase the hypertensive and vasoconstricting activities of Nylidrin.]
[H01CB02, octreotide, The risk or severity of adverse effects can be increased when Octreotide is combined with Bromocriptine.]
[S02AA16, ofloxacin, The therapeutic efficacy of Bromocriptine can be increased when used in combination with Ofloxacin.]
[J01FA05, oleandomycin, The serum concentration of Bromocriptine can be increased when it is combined with Oleandomycin.]
[N06AA05, opipramol, Opipramol may increase the vasopressor activities of Bromocriptine.]
[N02AA02, opium, The risk or severity of adverse effects can be increased when Bromocriptine is combined with Opium.]
[R03CB03, metaproterenol, Bromocriptine may increase the hypertensive and vasoconstricting activities of Orciprenaline.]
[G02CB04, quinagolide, The risk or severity of adverse effects can be decreased when Bromocriptine is combined with Quinagolide.]
[G04CA02, tamsulosin, Tamsulosin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Bromocriptine.]
[A14AA08, oxandrolone, Oxandrolone may increase the hypoglycemic activities of Bromocriptine.]
[N05BA04, oxazepam, The risk or severity of adverse effects can be increased when Oxazepam is combined with Bromocriptine.]
[J01MB05, oxolinic acid, The therapeutic efficacy of Bromocriptine can be increased when used in combination with Oxolinic acid.]
[C07AA02, oxprenolol, The therapeutic efficacy of Bromocriptine can be increased when used in combination with Oxprenolol.]
[N02AA05, oxycodone, The risk or severity of adverse effects can be increased when Oxycodone is combined with Bromocriptine.]
[C01DX03, oxyfedrine, Bromocriptine may increase the hypertensive and vasoconstricting activities of Oxyfedrine.]
[S01GA04, oxymetazoline, Bromocriptine may increase the hypertensive and vasoconstricting activities of Oxymetazoline.]
[A14AA05, oxymetholone, Oxymetholone may increase the hypoglycemic activities of Bromocriptine.]
[N02AA11, oxymorphone, The risk or severity of adverse effects can be increased when Oxymorphone is combined with Bromocriptine.]
[N05AE01, oxypertine, The risk or severity of adverse effects can be increased when Bromocriptine is combined with Oxypertine.]
[S01BC02, oxyphenbutazone, The risk or severity of hypertension can be increased when Bromocriptine is combined with Oxyphenbutazone.]
[A03AB03, oxyphenonium, Bromocriptine may increase the central nervous system depressant (CNS depressant) activities of Oxyphenonium.]
[J04AA01, aminosalicylic acid, Aminosalicylic acid may increase the hypoglycemic activities of Bromocriptine.]
[N05AH05, asenapine, Bromocriptine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Asenapine.]
[N02AX06, tapentadol, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Bromocriptine.]
[M03AC01, pancuronium, Bromocriptine may increase the central nervous system depressant (CNS depressant) activities of Pancuronium.]
[G04BE02, papaverine, The risk or severity of adverse effects can be increased when Papaverine is combined with Bromocriptine.]
[N05CC05, paraldehyde, Bromocriptine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.]
[H02AB05, paramethasone, The risk or severity of hyperglycemia can be increased when Paramethasone is combined with Bromocriptine.]
[C02KC01, pargyline, Pargyline may increase the hypertensive activities of Bromocriptine.]
[J01MA03, pefloxacin, The therapeutic efficacy of Bromocriptine can be increased when used in combination with Pefloxacin.]
[G04BD11, fesoterodine, Bromocriptine may increase the central nervous system depressant (CNS depressant) activities of Fesoterodine.]
[C07AA23, penbutolol, The therapeutic efficacy of Bromocriptine can be increased when used in combination with Penbutolol.]
[N05AG03, penfluridol, The risk or severity of adverse effects can be increased when Bromocriptine is combined with Penfluridol.]
[N02AD01, pentazocine, The risk or severity of adverse effects can be increased when Pentazocine is combined with Bromocriptine.]
[N05CA01, pentobarbital, The metabolism of Bromocriptine can be increased when combined with Pentobarbital.]
[N05AB10, perazine, The risk or severity of adverse effects can be increased when Bromocriptine is combined with Perazine.]
[N04BC02, pergolide, The risk or severity of adverse effects can be decreased when Pergolide is combined with Bromocriptine.]
[C08EX02, perhexiline, The risk or severity of hypotension can be increased when Bromocriptine is combined with Perhexiline.]
[N05AB03, perphenazine, The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Perphenazine.]
[N02AD02, phenazocine, The risk or severity of adverse effects can be increased when Bromocriptine is combined with Phenazocine.]
[N06AF03, phenelzine, Phenelzine may increase the hypertensive activities of Bromocriptine.]
[A10BA01, phenformin, The risk or severity of hypoglycemia can be increased when Phenformin is combined with Bromocriptine.]
[B01AA02, phenindione, The risk or severity of adverse effects can be increased when Bromocriptine is combined with Phenindione.]
[N03AA02, phenobarbital, The metabolism of Bromocriptine can be increased when combined with Phenobarbital.]
[N01AH04, phenoperidine, The risk or severity of adverse effects can be increased when Bromocriptine is combined with Phenoperidine.]
[C04AX02, phenoxybenzamine, Phenoxybenzamine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Bromocriptine.]
[B01AA04, phenprocoumon, The risk or severity of adverse effects can be increased when Bromocriptine is combined with Phenprocoumon.]
[A08AA01, phentermine, The therapeutic efficacy of Bromocriptine can be increased when used in combination with Phentermine.]
[V03AB36, phentolamine, Phentolamine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Bromocriptine.]
[M02AA01, phenylbutazone, The risk or severity of hypertension can be increased when Phenylbutazone is combined with Bromocriptine.]
[S01GA05, phenylephrine, Bromocriptine may increase the hypertensive and vasoconstricting activities of Phenylephrine.]
[R01BA01, phenylpropanolamine, Bromocriptine may increase the hypertensive and vasoconstricting activities of Phenylpropanolamine.]
[N03AB02, phenytoin, The metabolism of Bromocriptine can be increased when combined with Phenytoin.]
[S01AE05, levofloxacin, The therapeutic efficacy of Bromocriptine can be increased when used in combination with Levofloxacin.]
[C08CX01, mibefradil, The risk or severity of hypotension can be increased when Bromocriptine is combined with Mibefradil.]
[N05AG02, pimozide, The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Pimozide.]
[C07AA03, pindolol, The therapeutic efficacy of Bromocriptine can be increased when used in combination with Pindolol.]
[C10AA05, atorvastatin, The metabolism of Atorvastatin can be decreased when combined with Bromocriptine.]
[J05AE01, saquinavir, The serum concentration of Bromocriptine can be increased when it is combined with Saquinavir.]
[P02CB01, piperazine, The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Piperazine.]
[N05AC04, pipothiazine, The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Pipotiazine.]
[C09CA02, eprosartan, Bromocriptine may decrease the antihypertensive activities of Eprosartan.]
[A02BX03, pirenzepine, Bromocriptine may increase the central nervous system depressant (CNS depressant) activities of Pirenzepine.]
[N04BC08, piribedil, The risk or severity of adverse effects can be decreased when Bromocriptine is combined with Piribedil.]
[N02AC03, pirinitramide, The risk or severity of adverse effects can be increased when Bromocriptine is combined with Piritramide.]
[S01BC06, piroxicam, The risk or severity of hypertension can be increased when Piroxicam is combined with Bromocriptine.]
[J01MA11, grepafloxacin, The therapeutic efficacy of Bromocriptine can be increased when used in combination with Grepafloxacin.]
[N02CX01, pizotyline, Bromocriptine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Pizotifen.]
[J05AG02, delavirdine, The serum concentration of Bromocriptine can be increased when it is combined with Delavirdine.]
[C09CA04, irbesartan, Bromocriptine may decrease the antihypertensive activities of Irbesartan.]
[N05CA22, proxibarbal, The risk or severity of adverse effects can be increased when Bromocriptine is combined with Proxibarbal.]
[A10BG02, rosiglitazone, The risk or severity of hypoglycemia can be increased when Rosiglitazone is combined with Bromocriptine.]
[A03AE01, alosetron, The risk or severity of adverse effects can be increased when Alosetron is combined with Bromocriptine.]
[C03AA05, polythiazide, The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Polythiazide.]
[J05AE03, ritonavir, The serum concentration of Bromocriptine can be increased when it is combined with Ritonavir.]
[A10BH03, saxagliptin, The risk or severity of hypoglycemia can be increased when Saxagliptin is combined with Bromocriptine.]
[A10AD04, insulin lispro, The risk or severity of hypoglycemia can be increased when Bromocriptine is combined with Insulin lispro.]
[C07AB01, practolol, The therapeutic efficacy of Bromocriptine can be increased when used in combination with Practolol.]
[N05BA11, prazepam, The risk or severity of adverse effects can be increased when Bromocriptine is combined with Prazepam.]
[C02CA01, prazosin, Prazosin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Bromocriptine.]
[S03BA02, prednisolone, The risk or severity of hyperglycemia can be increased when Prednisolone is combined with Bromocriptine.]
[H02AB07, prednisone, The risk or severity of hyperglycemia can be increased when Prednisone is combined with Bromocriptine.]
[C01DX02, prenylamine, The risk or severity of hypotension can be increased when Bromocriptine is combined with Prenylamine.]
[N01BB04, prilocaine, The risk or severity of adverse effects can be increased when Prilocaine is combined with Bromocriptine.]
[P01BA03, primaquine, The metabolism of Bromocriptine can be decreased when combined with Primaquine.]
[N03AA03, primidone, The metabolism of Bromocriptine can be increased when combined with Primidone.]
[M04AB01, probenecid, The therapeutic efficacy of Bromocriptine can be increased when used in combination with Probenecid.]
[S01HA05, procaine, Procaine may increase the hypertensive activities of Bromocriptine.]
[L01XB01, procarbazine, Procarbazine may increase the hypertensive activities of Bromocriptine.]
[N05AB04, prochlorperazine, The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Prochlorperazine.]
[N04AA04, procyclidine, Bromocriptine may increase the central nervous system depressant (CNS depressant) activities of Procyclidine.]
[G03DA04, progesterone, The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Progesterone.]
[N05AA03, promazine, Promazine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Bromocriptine.]
[R06AD02, promethazine, Bromocriptine may increase the central nervous system depressant (CNS depressant) activities of Promethazine.]
[C01BC03, propafenone, The therapeutic efficacy of Bromocriptine can be increased when used in combination with Propafenone.]
[N01AX04, propanidid, The risk or severity of adverse effects can be increased when Bromocriptine is combined with Propanidid.]
[A03AB05, propantheline, Bromocriptine may increase the central nervous system depressant (CNS depressant) activities of Propantheline.]
[N05AC01, periciazine, Bromocriptine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Periciazine.]
[N05CM06, propiomazine, Propiomazine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Bromocriptine.]
[N01AX10, propofol, The risk or severity of adverse effects can be increased when Propofol is combined with Bromocriptine.]
[N02AC04, propoxyphene, The risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Bromocriptine.]
[C07AA05, propranolol, The therapeutic efficacy of Bromocriptine can be increased when used in combination with Propranolol.]
[N02CC04, rizatriptan, Bromocriptine may increase the vasoconstricting activities of Rizatriptan.]
[B01AC09, epoprostenol, Bromocriptine may decrease the antihypertensive activities of Epoprostenol.]
[N06AA11, protriptyline, Protriptyline may increase the vasopressor activities of Bromocriptine.]
[R01BA02, pseudoephedrine, The therapeutic efficacy of Pseudoephedrine can be decreased when used in combination with Bromocriptine.]
[N05AX12, aripiprazole, Bromocriptine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Aripiprazole.]
[A03AB15, diphemanil, Bromocriptine may increase the central nervous system depressant (CNS depressant) activities of Diphemanil.]
[A03AB09, isopropamide, Bromocriptine may increase the central nervous system depressant (CNS depressant) activities of Isopropamide.]
[S01FA03, methscopolamine, Bromocriptine may increase the central nervous system depressant (CNS depressant) activities of Methscopolamine.]
[N05CA07, talbutal, The risk or severity of adverse effects can be increased when Talbutal is combined with Bromocriptine.]
[N05CA09, vinbarbital, The risk or severity of adverse effects can be increased when Bromocriptine is combined with Vinbarbital.]
[N05BB02, captodiamine, The risk or severity of adverse effects can be increased when Bromocriptine is combined with Captodiame.]
[M03BA04, styramate, The risk or severity of adverse effects can be increased when Bromocriptine is combined with Styramate.]
[P02CC01, pyrantel, The risk or severity of adverse effects can be increased when Bromocriptine is combined with Pyrantel.]
[R06AC01, pyrilamine, The risk or severity of adverse effects can be increased when Bromocriptine is combined with Mepyramine.]
[C01BA01, quinidine, Quinidine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Bromocriptine.]
[P01BC01, quinine, The risk or severity of hypoglycemia can be increased when Quinine is combined with Bromocriptine.]
[D07AC10, diflorasone, The risk or severity of hyperglycemia can be increased when Diflorasone is combined with Bromocriptine.]
[C02AA01, rescinnamine, Bromocriptine may decrease the antihypertensive activities of Rescinnamine.]
[C02AA02, reserpine, The risk or severity of adverse effects can be increased when Bromocriptine is combined with Reserpine.]
[J04AB02, rifampin, The metabolism of Bromocriptine can be increased when combined with Rifampicin.]
[R03AC05, rimiterol, Bromocriptine may increase the hypertensive and vasoconstricting activities of Rimiterol.]
[G02CA01, ritodrine, Bromocriptine may increase the hypertensive and vasoconstricting activities of Ritodrine.]
[N06AX01, 5-hydroxytryptophan, The risk or severity of adverse effects can be increased when Bromocriptine is combined with Oxitriptan.]
[J01FA06, roxithromycin, Roxithromycin may increase the vasoconstricting activities of Bromocriptine.]
[N02BA05, salicylamide, The risk or severity of hypertension can be increased when Bromocriptine is combined with Salicylamide.]
[A07EC01, sulfasalazine, Sulfasalazine may increase the hypoglycemic activities of Bromocriptine.]
[S01BC08, salicylic acid, Salicylic acid may increase the hypoglycemic activities of Bromocriptine.]
[S01FA02, scopolamine, Bromocriptine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N05CA06, secobarbital, Secobarbital may increase the hypotensive activities of Bromocriptine.]
[N04BD01, selegiline, Selegiline may increase the hypertensive activities of Bromocriptine.]
[L01FA03, obinutuzumab, The risk or severity of adverse effects can be increased when Bromocriptine is combined with Obinutuzumab.]
[H01CB01, somatostatin, The serum concentration of Bromocriptine can be increased when it is combined with Somatostatin.]
[C07AA07, sotalol, The risk or severity of hypoglycemia can be increased when Sotalol is combined with Bromocriptine.]
[C03DA01, spironolactone, The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Spironolactone.]
[N03AG01, valproic acid, The risk or severity of adverse effects can be increased when Valproic acid is combined with Bromocriptine.]
[D07AB02, hydrocortisone butyrate, The risk or severity of hyperglycemia can be increased when Hydrocortisone butyrate is combined with Bromocriptine.]
